



撥康視云™
Cloudbreak Pharma

Cloudbreak Pharma Inc.
撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)

Stock Code 股份代號 : 2592



2025

Environmental, Social and
Governance Report
環境、社會及管治報告



* For identification purpose only
僅供識別

目錄

Contents

Message from Our Chairman	1
主席致辭	
About this report	2
有關本報告	
Board Statement	2
董事會聲明	
Reporting Boundary and Reporting Period	2
報告範圍及報告期間	
Reporting Framework	2
報告框架	
Sustainability Management Approach	3
可持續發展管理方法	
Sustainability Governance Structure	3
可持續發展管治架構	
Materiality Assessment	5
重要性評估	
Stakeholders' Engagement	7
持份者參與	
Environmental Stewardship & Management	8
環境監管及管理	
Our commitment	8
我們的承諾	
Climate Change	9
氣候變化	
Resource Stewardship & Circularity	19
資源管理及循環發展	
People Wellbeing & Engagement	22
員工福祉及參與	
Labour Standards	22
勞工準則	
Occupational Health and Safety	24
職業健康與安全	
Development and Training	26
發展及培訓	
Community Impact	28
社區影響	
Operational Excellence & Responsible Governance	29
卓越營運及責任管治	
Responsible supply chain	29
責任供應鏈	
Clinical Trial Safety	30
臨床試驗安全	
Data-security	31
數據安全	
Anti-corruption	31
反貪污	
Content Index	32
內容索引	
HKEX ESG Reporting Code Content Index	32
香港交易所《環境、社會及管治報告守則》內容索引	



主席致辭

Message from Our Chairman

On behalf of the Board of Directors, I am pleased to present Cloudbreak Pharma Inc.'s first ESG Report. Since our founding in 2015, we have been dedicated to discovering and developing novel, differentiated treatments for patients suffering from eye diseases worldwide. We firmly believe that scientific excellence must be pursued alongside responsible corporate citizenship, and the Board maintains overall responsibility for overseeing our ESG strategy, ensuring sustainability is embedded in our risk management and decision-making processes.

During the reporting period, we took meaningful action to strengthen our sustainability foundation. We implemented a comprehensive Environmental, Health and Safety management system supported by a four-tier governance structure. We have set measurable targets to reduce electricity consumption, water consumption, and hazardous waste generation per unit of R&D investment by 2% by the end of 2027. Operational measures – including energy-efficient equipment, occupancy-based utility controls, rigorous waste segregation, and licensed third-party disposal – are already underway. We have also assessed our exposure to physical and transition climate risks and integrated these considerations into our enterprise risk assessment framework.

Our commitment to our people and ethical conduct remains unwavering. We recorded zero work-related injuries and zero lost workdays during the reporting period, and our clinical trial safety framework ensures rigorous oversight and patient protection. As of December 2025, approximately 55% of our employees were female, reflecting our dedication to diversity and inclusion. We place strong emphasis on business ethics, anti-corruption, and community engagement, and continuously work to strengthen our approach across these important ESG areas.

Looking ahead, as we progress toward commercialisation, we will continue to enhance our ESG disclosures, strengthen our focus on product quality, patient privacy, and data security, and further integrate climate considerations into our strategic planning. I extend my sincere gratitude to our employees, clinical trial participants, shareholders, and partners for their trust and support. Together, we will advance science, protect sight, and build a more sustainable future.

Dr. Ni Jinsong
Chairman of the Board

本人謹代表董事會，欣然提呈撥康視雲製藥有限公司的首份環境、社會及管治報告。自2015年成立以來，我們一直致力於全球眼疾患者探索及開發嶄新且具針對性的治療方案。我們堅信，在追求卓越科學的同時，須履行負責任的企業公民責任，且董事會全面負責監督本公司的環境、社會及管治策略，確保可持續發展理念融入我們的風險管理及決策流程。

於報告期間，我們採取切實有效的措施以鞏固可持續發展基礎。我們實施全面的環境、健康及安全管理系統，並由四級管治架構支持。我們已設定可量化的目標，力求於2027年底前將每單位研發投資的耗電、耗水和有害廢棄物產生量減少2%。我們已展開多項營運措施，包括節能設備、按使用情況調控公共設施、嚴格的廢棄物分類及經許可的第三方處置。我們亦評估自身所面臨的實體及轉型氣候風險，並將該等因素納入企業風險評估框架。

我們對員工的福祉以及道德操守的承諾始終堅定不移。於報告期間，我們錄得零工傷事故及零工時損失，且臨床試驗安全框架確保嚴格的監督及患者保護。截至2025年12月，我們約55%的僱員為女性，反映我們致力於推動多元化及包容性。我們高度重視商業道德、反貪污及社區參與，並持續努力加強該等重要環境、社會及管治領域的實踐方針。

展望未來，在邁向商業化的進程中，我們將繼續加強環境、社會及管治的資料披露，更加注重產品質量、患者私隱及數據安全，並進一步將氣候因素納入策略規劃。本人衷心感謝員工、臨床試驗參與者、股東及合作夥伴的信任與支持。我們將攜手推動科學發展，守護視力健康，共建更可持續發展的未來。

Ni Jinsong博士
董事會主席

BOARD STATEMENT

This Report outlines the environmental, social, and governance (“**ESG**”) commitments, management approach, and performance of Cloudbreak Pharma Inc. (“**Cloudbreak**”, “**the Company**”, “**we**”) and all of its subsidiaries (“**Group**”). We are a global, clinical-stage ophthalmology biotechnology company dedicated to discovering and developing novel and differentiated treatments for eye diseases. Our history traces back to 2015, and our pipeline includes two Core Products, CBT-001 and CBT-009, currently in advanced clinical trials, alongside several earlier-stage drug candidates.

REPORTING BOUNDARY AND REPORTING PERIOD

The operational boundary of this Report encompasses our global presence, including our offices and facilities in the United States, Hong Kong, Mainland China, Germany, and Australia. The Report details our ESG governance structure, risk management strategies, and key initiatives across environmental stewardship, employee wellbeing, and product responsibility. It covers the period from 1 January 2025 to 31 December 2025 for strategic commitments and forward-looking targets.

REPORTING FRAMEWORK

This Report has been compiled in accordance with the Environmental, Social and Governance Reporting Code (Appendix C2) issued by The Stock Exchange of Hong Kong Limited (the “**HKEX ESG Reporting Code**”) and adheres to the four reporting principles set out therein: Materiality, Quantitative, Balance, and Consistency. A content index mapping our disclosures to the HKEX ESG Code is provided at the end of this Report to enhance transparency and accessibility for our stakeholders.

董事會聲明

本報告概述撥康視雲製藥有限公司（「撥康視雲」、「本公司」、「我們」）及所有附屬公司（「本集團」）在環境、社會及管治（「ESG」）方面的承諾、管理方法及績效。我們是一家全球性臨床階段眼科生物科技公司，致力於探索及開發嶄新且具針對性的眼疾治療方案。我們的歷史可追溯至2015年，管線包含兩款核心產品CBT-001及CBT-009（目前處於後期臨床試驗階段）以及多款早期候選藥物。

報告範圍及報告期間

本報告的運營範圍涵蓋我們在全球的業務佈局，包括美國、香港、中國內地、德國及澳洲的辦事處及設施。報告詳細闡述ESG管治架構、風險管理策略，以及在環境監管、員工福祉及產品責任方面的關鍵舉措。報告涵蓋2025年1月1日至2025年12月31日期間的策略承諾及前瞻性目標。

報告框架

本報告乃根據香港聯合交易所有限公司刊發的《環境、社會及管治報告守則》（附錄C2）（「香港交易所ESG守則」）編製，並遵守當中載列的四項報告原則：重要性、量化、平衡及一致性。報告末尾附有內容索引，將披露內容與香港交易所ESG守則進行對照，以提升持份者的透明度及可及性。

可持續發展管理方法

Sustainability Management Approach

SUSTAINABILITY GOVERNANCE STRUCTURE

Cloudbreak has established a robust, multi-tiered governance framework dedicated to the effective oversight and management of ESG matters. This structure is designed to ensure that ESG considerations are systematically integrated into our strategic decision-making, risk management, and daily operations, aligning our business growth with long-term sustainability and resilience.

The cornerstone of our approach is a clearly defined four-level management structure that delineates responsibilities from strategic oversight to operational execution. This hierarchical model ensures comprehensive coverage of ESG issues, from board-level strategy setting to on-the-ground risk response, facilitating clear accountability and informed decision-making at every level.

Our governance is dynamic and proactive, employing a continuous cycle of identification, assessment, management, and review. We utilise various strategies to stay ahead of emerging risks and opportunities, including benchmarking against industry peers, engaging in regular dialogue with internal management and external stakeholders, and developing specific risk management approaches with quantified performance indicators. This systematic process is subject to regular review under the direct supervision of our Board and senior management, ensuring our strategies remain relevant and effective in a changing landscape.

The specific roles and responsibilities within our four-tier governance models are detailed in the table below:

Entity/Role 實體／角色	Primary Responsibilities 主要職責
Board of Directors 董事會	<ul style="list-style-type: none"> Overall oversight of ESG & climate-related risks/opportunities Conduct an annual review of targets to ensure they remain relevant, achievable, and effective in driving the Group's sustainability and performance objectives Evaluation of monitoring mechanisms Ensuring proper disclosure Strategy refinement and approval Cross-entity coordination (China, HK, USA) 全面監督ESG及氣候相關風險／機會 每年對目標進行審閱，以確保其持續相關、可實現且能有效推動本集團可持續發展及績效目標 評估監控機制 確保適當披露 策略優化及審批 跨實體合作(中國、香港、美國)

可持續發展管治架構

撥康視雲已建立穩健的多層級管治框架，專責有效地監督及管理ESG事務。該架構旨在確保ESG考量系統化納入策略決策、風險管理及日常營運，使業務增長與長期可持續發展及韌性目標保持一致。

我們方針的核心為界定清晰的四級管理架構，其明確劃分從策略監督到營運執行的各項職責。該層級模型確保ESG議題從董事會層面的策略制定到實際風險應對均能得到全面覆蓋，從而促使在各層級實現明確問責及知情決策。

我們的管治模式具有動態性和積極性，採用持續識別、評估、管理、檢討循環。我們利用多種策略來提前應對新興風險及機遇，包括與同業進行基準比較、定期與內部管理層及外部持份者進行溝通，並制定可量化績效指標的具體風險管理方法。該系統化流程在董事會及高級管理層的直接監督下定期進行檢討，以確保我們的策略在不斷變化的環境中依然具有相關性及有效性。

下表詳述本集團四級管治模式中的具體角色及職責：

SUSTAINABILITY GOVERNANCE STRUCTURE (continued)

可持續發展管治架構 (續)

Entity/Role 實體／角色	Primary Responsibilities 主要職責
Environment, Health and Safety (“EHS”) Manager 環境、健康及安全 (「EHS」) 經理	<ul style="list-style-type: none"> Policy implementation & monitoring Regulatory tracking & updates Internal/external communication facilitation Performance reporting to management <ul style="list-style-type: none"> 政策執行及監督 法規追蹤及更新 內部／外部溝通協調 向管理層提交績效報告
ESG Working Group (Consists of the head of global human resources department, the company secretaries, the Suzhou facility head/government relations director, a director of R&D and a clinical research assistant) ESG工作小組 (包括全球人力資源部負責人、公司秘書、蘇州工廠負責人／政府關係總監、研發總監及臨床研究助理)	<ul style="list-style-type: none"> Climate-related risk and opportunity assessment & management Working rules & implementation measures formulation Internal system review & disclosure preparation Regular meetings & annual reporting to Board for findings on climate risks & opportunities assessment <ul style="list-style-type: none"> 氣候相關風險及機會評估及管理 工作規則及實施細則制定 內部系統審閱及披露準備 定期召開會議並向董事會提交年報，匯報氣候風險及機會評估結果
EHS Team & Entity-Level Management EHS團隊及實體層面管理	<ul style="list-style-type: none"> Frontline risk investigation & response Assessment reports & emergency planning Entity-specific risk identification & evaluation Data collection for Enterprise Risk Management (“ERM”) integration <ul style="list-style-type: none"> 一線風險調查及應對 評估報告及應急計劃 實體特定風險識別及評估 企業風險管理整合數據收集

This integrated governance structure empowers Cloudbreak to proactively navigate the complex ESG landscape, ensuring that our commitment to sustainability is deeply embedded in our corporate fabric and drives continuous improvement toward our strategic objectives.

該綜合管治架構使撥康視雲積極應對複雜 ESG 情況的能力，確保可持續發展的承諾深深根植企業文化中，並推動我們持續邁向策略目標。

可持續發展管理方法

Sustainability Management Approach

MATERIALITY ASSESSMENT

To ensure our ESG reporting focuses on the issues that matter most to our business and stakeholders, Cloudbreak conducted a structured materiality assessment during the reporting period. This process involved benchmarking industry practice and considering input from internal and external stakeholders through engagement activities. Through this assessment, we identified six material topics that represent our most significant ESG impacts and form the core of our sustainability strategy.

- **Climate Change:** Climate change presents both physical and transition risks to Cloudbreak's operations. Physical risks, such as increased frequency of extreme weather events, may disrupt our supply chain, damage facilities, or affect employee safety. Transition risks, including evolving low-carbon regulations and stakeholder expectations for emissions transparency, create compliance and reputational pressures. Conversely, we see opportunities to lead in low-carbon pharmaceutical R&D and manufacturing by improving energy efficiency and exploring cleaner technologies. Proactive climate risk management strengthens our resilience and demonstrates our commitment to environmental stewardship and exploring cleaner technologies.
- **Occupational Health and Safety:** As a clinical-stage biotechnology company, the health and safety of our employees, particularly those working with hazardous materials in laboratories and pilot facilities – is our highest priority. Effective occupational health and safety management prevents workplace injuries and illnesses, ensures compliance with regulatory requirements, and fosters a culture of care and productivity. Our robust EHS framework, regular training, and incident-free track record reflect our dedication to a safe working environment.

重要性評估

為確保我們的ESG報告聚焦於對我們的業務及持份者至關重要的議題，撥康視雲於報告期間進行結構化的重要性評估。該過程涉及對行業實踐進行標準比較，並通過參與活動考慮內部及外部持份者的意見。通過此評估，我們識別六項重大議題，這些議題代表我們最重要的ESG影響，並構成可持續發展策略的核心。

- **氣候變化：**氣候變化為撥康視雲的營運帶來實體及轉型風險。實體風險，例如極端天氣事件發生的頻率增加，可能會擾亂我們的供應鏈、損壞設施或影響員工安全。轉型風險，包括不斷變化的低碳法規及持份者對排放透明度的期望，帶來合規及聲譽壓力。相反，我們透過提高能源效益及探索更清潔的技術，把握在低碳製藥研發及製造方面的領先機遇。積極主動的氣候風險管理增強我們的抵禦能力，並彰顯我們對環境保護及探索更清潔技術的承諾及決心。
- **職業健康與安全：**作為一家臨床階段生物科技公司，我們將僱員的健康與安全，特別是那些在實驗室及中試設施處理危險物料的僱員，視為最高優先事項。有效的職業健康及安全管理可預防工作場所傷害及疾病，確保符合法規要求，並培養關愛及高效的文​​化。我們穩健的EHS框架、定期培訓及零事故紀錄，充分反映我們對安全工作環境的承諾。

MATERIALITY ASSESSMENT (continued)

- **Product Quality and Safety:** Our mission to develop novel ophthalmic therapies depends on the trust of patients, healthcare professionals, and regulators. Product quality and safety are non-negotiable. We maintain rigorous quality controls throughout our R&D and clinical manufacturing processes, adhering to Good Manufacturing Practice (“GMP”) standards and pharmacovigilance requirements. By ensuring our drug candidates meet the highest safety and quality standards, we protect patients and uphold the integrity of our scientific advancements.
- **Privacy and Data Security:** Our clinical trial activities involve the collection and processing of sensitive personal data, including patient health information and trial participant records. Protecting this data from unauthorised access, breaches, or misuse is both a legal obligation and a cornerstone of stakeholder trust.
- **Product Innovation and R&D:** As a clinical-stage biotechnology company, our ability to innovate and advance our pipeline is fundamental to our long-term value creation. Investment in research and development drives the discovery of differentiated treatments for unmet medical needs, positioning us at the forefront of ophthalmic science. This topic reflects our core business purpose and is closely monitored by investors, partners, and the scientific community. By fostering a culture of innovation, protecting intellectual property, and collaborating with academic and clinical experts, we deliver meaningful impact for patients and sustainable growth for our shareholders.
- **Anti-corruption and Business Ethics:** Maintaining the highest standards of integrity and ethical conduct is essential to our corporate reputation and operational legitimacy. As we expand our global footprint, we face varying regulatory environments and potential exposure to bribery, fraud, or other improper practices. Strong business ethics mitigate legal and financial risks, build trust with stakeholders, and ensure we operate responsibly in every market we serve.

重要性評估 (續)

- **產品質量及安全：**我們開發新型眼科療法的使命取決於患者、醫療保健專業人員及監管機構的信任。產品品質和安全性是不容妥協的。在研發和臨床生產流程中，我們始終嚴格把控品質，遵循良好生產規範(「GMP」)標準和藥物警戒要求。通過確保我們的候選藥物符合最高的安全及品質標準，我們保障患者並維護科學進步的完整性。
- **私隱及數據安全：**我們的臨床試驗活動涉及收集及處理敏感個人數據，包括患者健康信息及試驗參與者記錄。保護有關數據免遭未經授權訪問、洩露或濫用，既是法律義務，亦是持份者信任的基石。
- **產品創新及研發：**作為臨床階段的生物技術公司，創新能力及推進產品管線的能力，是我們創造長期價值的根本。研發投資推動針對未滿足醫療需求的針對性療法發現，使我們始終處於眼科科學前沿。該議題反映我們的核心商業宗旨，受到投資者、合作夥伴及科學界的密切關注。通過培育創新文化、保護知識產權、以及與學術及臨床專家合作，我們為患者創造有意義的影響，並為股東實現可持續增長。
- **反貪污及商業道德：**秉持最高的誠信標準和道德規範，對維護企業聲譽及運營合法性至關重要。隨著全球業務拓展，我們面臨不同的監管環境並可能面臨賄賂、欺詐或其他不當行為的風險。堅實的商業道德可降低法律及財務風險，建立與持份者的信任，並確保我們在所服務的每個市場均負責任地營運。

可持續發展管理方法

Sustainability Management Approach

STAKEHOLDERS' ENGAGEMENT

We identify and prioritise material ESG topics through a structured review of input from our key stakeholder groups. Regular engagement via established channels allows us to gather relevant feedback to inform our approach and reporting.

持份者參與

我們通過對主要持份者組別的意見進行結構性檢視，以識別及優先處理重大的ESG議題。借助既定渠道進行定期溝通，讓我們能夠收集相關反饋，從而知所依循，制定方針及匯報工作。

Key Stakeholder Group 主要持份者組別	Engagement Channel 參與渠道
Shareholders and Investors 股東及投資者	<ul style="list-style-type: none"> Annual general meetings Financial reports Corporate communications Dedicated meetings 股東週年大會 財務報告 企業通訊 專項會議
Employees 僱員	<ul style="list-style-type: none"> Internal surveys Staff activities 內部問卷調查 員工活動
Business Partners (Suppliers/Contractors) 業務夥伴(供應商/承包商)	<ul style="list-style-type: none"> Tendering processes Operational and contract review meetings Site visits 招標流程 營運及合約審查會議 實地考察
Government & Regulatory Bodies 政府及監管機構	<ul style="list-style-type: none"> Participation in industry committees, forums, and operational meetings 參加行業委員會、論壇及營運會議
Healthcare Professionals and Academia 醫療保健專業人員及學術界	<ul style="list-style-type: none"> Engagement through clinical trial interactions, scientific collaborations 通過臨床試驗互動及科學合作參與
Media 媒體	<ul style="list-style-type: none"> Press releases Executive interviews Media briefings 新聞發佈 行政人員訪談 媒體簡報會

These ongoing dialogues support our management of material sustainability topics.

該等持續對話有助於我們對重大可持續發展議題的管理。

OUR COMMITMENT

The Company is committed to conducting its operations responsibly and in full compliance with all relevant environmental laws and regulations across the jurisdictions in which we operate. Regulatory compliance forms the foundation of our sustainability approach and reflects the expectations of our stakeholders.

In order to ensure that our R&D and the future production are in compliance with the applicable laws and regulations, we have implemented a series of rules, standard operating procedures and measures with effect from 7 April 2023 on environmental, health and safety matters (“EHS”), which we believe are in line with industry standards and in compliance with the requirements of the Listing Rules. In addition, all of the Group’s operations are in compliance with relevant laws and regulations.

Our EHS policies include general EHS risk assessment methodology and risk management measures for EHS. Specifically, for environmental matters, we have adopted plan for environmental management system, management measures for hazardous chemical substance and other waste, and procedures for manufacturing area and building cleaning, covering (i) treatment of solid waste, (ii) adoption of materials that cause minimum environmental concerns to the extent possible, and (iii) hygiene sampling of airborne contaminants, among other aspects.

For employee safety and welfare matters, we have adopted procedures for manufacturing area and building cleaning, procedures for first aid, policies on personal protective equipment, and the internal training measures for EHS, covering (i) clinical trial safety, (ii) employee health, promotion, compensation and benefits, and (iii) employee training, wellness and professional and personal development, among other aspects. We are also committed to complying with ESG reporting requirements upon listing.

Beyond compliance, we place strong emphasis on environmental stewardship and the continuous improvement of our management practices. We have established internal procedures to monitor performance, ensure accountability, and regularly review our operations to minimise environmental impact. Our approach prioritises responsible resource management, climate risk awareness, and alignment with the expectations of regulators, investors, and the communities we serve.

我們的承諾

本公司致力於以負責任的方式開展業務，並全面遵守我們營運所在司法權區所有相關環境法律法規。監管合規為我們的可持續發展方針的基礎，並反映我們持份者的期望。

為確保我們的研發和未來的生產符合適用的法律法規，我們實施一系列有關環境、健康及安全事項（「EHS」）的規則、標準操作程序和措施，自2023年4月7日起生效，我們認為該等規則、標準操作程序和措施符合行業標準並符合上市規則的要求。此外，本集團所有的營運活動均嚴格遵守相關法律法規的要求。

我們的EHS政策包括一般EHS風險評估方法和EHS風險管理措施。具體而言，在環境問題上，我們採用環境管理系統計劃、有害化學物質和其他廢棄物管理措施以及生產區和樓宇清潔程序，涵蓋：(i)固體廢棄物處理；(ii)盡可能採用對環境影響最小的材料；及(iii)空氣中污染物的衛生採樣等方面。

在員工安全和福利方面，我們制定生產區和樓宇清潔程序、急救程序、個人防護設備政策和EHS內部培訓措施，涵蓋：(i)臨床試驗安全；(ii)員工健康、晉陞、薪酬和福利；及(iii)員工培訓、福祉、專業及個人發展等。我們亦承諾在上市後遵守ESG報告守則。

在合規要求之外，我們高度重視環境監管，並持續改進管理實踐。我們已制定內部程序以監控績效、確保問責制，並定期檢視我們的運營，從而將對環境的影響降至最低。我們的方法優先考慮負責任的資源管理、氣候風險意識，並與監管機構、投資者以及我們所服務的社區的期望保持一致。

環境監管及管理

Environmental Stewardship & Management

CLIMATE CHANGE

During the reporting year, the Group strengthened its climate-related disclosure practices to align with the requirements of HKEX ESG Code. For areas where full disclosure is not yet practicable, the relevant information gaps and underlying considerations are outlined in this chapter under the section titled “HKEX ESG Reporting Code Content Index”.

Governance

The Group integrates the management of ESG-related risks and opportunities into its overall governance framework, ensuring that climate considerations are systematically embedded into strategic planning, business decisions, and resource allocation processes. Climate-related governance forms an essential component of the Group’s wider ESG oversight structure.

Oversight of ESG and climate-related matters rests with the Board. To ensure the Board maintains appropriate knowledge and competencies to oversee strategies addressing climate-related risks and opportunities, the Group provides ongoing training and relevant resources to strengthen the Board’s understanding of key climate issues, regulatory developments and their potential impact on the Group’s business. This enables the Board to exercise informed and effective oversight of climate-related strategies and sustainability-related challenges. The Board regularly reviews the adequacy of internal mechanisms to monitor and manage ESG issues, and assesses progress of climate-related initiatives.

In overseeing the Group’s strategy, the Board explicitly takes climate-related risks and opportunities into account when reviewing major transactions, risk management processes and related policies. During its evaluation of material business decisions, the Board considers the potential climate-related implications and associated risks, ensuring that such factors are duly identified, assessed and reflected in the Group’s long-term strategic decisions and overall risk management framework.

The Board is also responsible for setting climate-related targets and annually overseeing progress against these targets. Performance against such targets is reviewed and adjusted as necessary, with results disclosed publicly to stakeholders. Where appropriate, relevant performance indicators are incorporated into the management accountability framework, thereby reinforcing the importance of ESG and climate management throughout the organisation. The Group’s compensation practice is also linked to performance indicators, which include ESG-related indicators and work safety management.

氣候變化

於報告年度內，本集團加強了氣候相關披露實踐，以符合香港交易所ESG守則的要求。對於尚未能全面披露的領域，相關信息缺口及相關考慮因素已在本章「香港交易所《環境、社會及管治報告守則》內容索引」一節進行概述。

管治

本集團將ESG相關風險及機會的管理納入整體管治框架，確保氣候考慮因素系統性地融入策略規劃、業務決策及資源配置流程中。氣候相關管治是本集團廣泛的ESG監管架構的重要組成部分。

ESG及氣候相關事項的監管職責由董事會負責。為確保董事會具備適當專業知識及能力監督應對氣候相關風險及機會的策略，本集團提供持續培訓及相關資源，以加強董事會對關鍵氣候議題、監管發展及其對本集團業務潛在影響的理解。此舉使董事會能夠對氣候相關策略及可持續發展挑戰實施知情且有效的監督。董事會定期檢討內部機制在監察及管理ESG議題方面的充分性，並評估氣候相關措施的進展。

在監督本集團策略的過程中，董事會在審查重大交易、風險管理流程及相關政策時，會明確考慮到與氣候相關的風險及機會。於評估重大業務決策時，董事會將考慮潛在氣候相關影響及風險，確保該等因素獲適當識別、評估，並在本集團的長期策略決策及整體風險管理框架中有所體現。

董事會亦負責制定與氣候相關的目標，並每年監督該等目標的實現進度。我們會對該等目標的表現進行檢討，並根據需要進行調整，同時向持份者公開披露相關結果。於適當情況下，相關績效指標會納入管理問責框架中，從而強化ESG及氣候管理在整個組織中的重要性。本集團的薪酬制度亦與包括環境、社會及管治及安全生產管理等指標掛鉤。

CLIMATE CHANGE (continued)

Strategy

Climate-related risks and opportunities

As a clinical-stage ophthalmology biotechnology company focused on the development of novel and differentiated treatments, Cloudbreak may be exposed to climate-related risks, which can be divided into two broad categories: physical and transition risks.

- Physical risks include acute impacts such as increased severity of typhoons or floods, as well as chronic impacts from long-term changes in climate patterns, such as shifts in average annual rainfall or temperature.
- Transition risks arise from the global move towards a low-carbon economy, encompassing changes in policy, laws, technology, markets, and social expectations – for example, carbon taxes, compliance disclosures, and increased adoption of renewable energy sources.

The ESG-related risks and the actual and potential impact of such risks on our business, strategy, and financial performance are summarised below:

Type of Risks 風險類別			Potential Impact 潛在影響
Physical risks 實體風險	Acute risks 急性風險	Frequent occurrence of typhoons, floods, droughts and other extreme weather 頻繁發生颱風或洪水、乾旱及其他極端天氣	<ul style="list-style-type: none"> Interruption of supplies or business 供應或業務中斷
	Chronic risks 慢性風險	Rising average temperature 平均氣溫上升	<ul style="list-style-type: none"> Increased energy consumption in laboratories, factories and offices resulting in higher energy costs Decreased employee productivity and increased labour costs 實驗室、工廠及辦公室的能源消耗增加，導致能源成本上升 僱員生產力降低及勞工成本上升
Transition risks 轉型風險	Policy and legal risks 政策及法律風險	Industry low-carbon policy requirements and tightening regulatory requirements 行業低碳政策規定及監管收緊規定	<ul style="list-style-type: none"> Pressure on carbon costs Government's quotas allocation on carbon emission and pressure on carbon costs 碳成本壓力 政府的碳排放配額分配及碳成本壓力

氣候變化 (續)

策略

氣候相關風險及機會

作為一間致力於開發新型及針對性療法的臨床階段眼科生物科技公司，撥康視雲可能面臨氣候相關風險，該等風險可分為兩大類：實體風險及轉型風險。

- 實體風險包括突發性的直接影響，如颱風或洪水的嚴重程度增加，以及受長期氣候模式轉變導致的影響，如年平均降雨量或溫度的變化。
- 轉型風險源於全球向低碳經濟的轉變，涵蓋政策、法律、技術、市場及社會期望的變化，例如碳稅、合規披露要求，以及可再生能源應用的普及。

ESG相關風險以及此類風險對我們的業務、策略及財務表現的實際及潛在影響概述如下：

環境監管及管理

Environmental Stewardship & Management

CLIMATE CHANGE (continued)

Strategy (continued)

Climate-related risks and opportunities (continued)

氣候變化 (續)

策略 (續)

氣候相關風險及機會 (續)

Type of Risks 風險類別		Potential Impact 潛在影響
	Litigation risk 訴訟風險	<ul style="list-style-type: none"> Litigation risk brought from the interruption of supply chain, resulting in our failure to perform future contracts on time 供應鏈中斷帶來的訴訟風險，導致我們無法按時履行未來合約
Market and technology risks 市場及技術風險	Costs for transition to low-carbon emission technology 過渡至低碳排放技術的成本	<ul style="list-style-type: none"> Increased cost on upgrading facilities in laboratories, factories and offices for energy saving and high efficiency 升級實驗室、工廠及辦公室的節能高效設施導致成本增加
	Rising raw material costs 原材料成本上升	<ul style="list-style-type: none"> Decreased quantity and quality of raw materials Increased R&D costs resulting from insufficient resources of laboratory supplies 原材料數量減少及質量下降 實驗室用品資源不足導致研發成本上升
	Changes in customer behaviour and preferences 客戶行為及偏好變動	<ul style="list-style-type: none"> Loss of future orders and decreased future revenue resulting from insufficient disclosure of carbon neutrality goals and data Demand from downstream future corporate customers to upstream suppliers to provide green and low-carbon biomedical products and to formulate carbon-neutral strategic goals 未充分披露碳中和目標及數據導致損失未來訂單及減少未來收益 未來下游企業客戶要求上游供應商提供綠色低碳生物醫藥產品，並制定碳中和策略目標

CLIMATE CHANGE (continued)

氣候變化 (續)

Strategy (continued)

策略 (續)

Climate-related risks and opportunities (continued)

氣候相關風險及機會 (續)

Type of Risks 風險類別		Potential Impact 潛在影響	
	Uncertain demand		<ul style="list-style-type: none"> Possible increased demand for medicines and other pharmaceutical products resulting from the emergence of new chronic diseases and other diseases
	不確定需求		<ul style="list-style-type: none"> 新型慢性疾病及其他疾病的出現可能導致對藥品及其他醫藥產品的需求增加
	Reputational risk	Negative publicity	<ul style="list-style-type: none"> Negative publicity on our reputation resulting from our inability to respond to stakeholders expectation caused by insufficient disclosure on the reduction targets and information on emission
	聲譽風險	負面輿情	<ul style="list-style-type: none"> 由於未充分披露排放減少目標及資料，無法滿足持份者的期望，從而對我們的聲譽產生負面影響
Type of Opportunities 機會類別		Potential Impact 潛在影響	
Opportunities 機會	Emerging markets and Product	<ul style="list-style-type: none"> Increased demand for low-carbon solutions, sustainable technologies, and innovative treatment 	<ul style="list-style-type: none"> Changing climate conditions may create emerging opportunities for Cloudbreak, as shifts in temperature, air quality, and UV exposure can affect ocular health and drive demand for innovative ophthalmic treatments.
	新興市場及產品	<ul style="list-style-type: none"> 對低碳解決方案、可持續發展技術和創新治療方案的需求日益增長 	<ul style="list-style-type: none"> 不斷變化的氣候條件可能為撥康視雲創造新的機遇，因為溫度、空氣品質及紫外線照射的變化會影響眼部健康，從而推動對創眼科治療方案的需求。

環境監管及管理

Environmental Stewardship & Management

CLIMATE CHANGE (continued)

Strategy (continued)

Climate-related risks and opportunities (continued)

In view of the nature of our business, to the best knowledge of our Directors, the climate change will not have any major impact on our business operation. In the case of extreme natural weather, we will actively respond to the relevant policies of local government, make contingency plans in addition to the life insurance contributed by our Group to ensure the safety of our staff. In the case of acute physical risks such as direct damage to assets and indirect impacts from supply chain disruption as a result of extreme weather events, we will make corresponding contingency and disaster preparedness plans, and we believe that we have the ability to deal with climate crisis. During the reporting period, we had not experienced any material impact on our business operations, strategies or financial performance as a result of environmental, social and climate-related issues.

Our Group conducts an enterprise risk assessment at least once a year to cover current and potential risks faced by the Group, including but not limited to risks arising from ESG aspects and strategic risks related to disruptive forces such as climate change. The Board assesses these risks or engages external experts to conduct independent evaluations, and reviews the Group's existing strategies, targets and internal controls. Necessary improvements are implemented to mitigate identified risks. The Board, the Audit Committee, the EHS manager and the ESG working group maintain oversight of the Group's risk management approach, including climate-related risks and risks monitored under standard operating processes, to ensure appropriate mitigation measures are in place through regular management reviews.

The decisions on the reduction, transfer, acceptance or control of the risks are affected by various factors such as government regulation and the availability of energy-saving supplies. We will incorporate climate-related issues, including the analysis on physical and transition risks, into our risk assessment process and risk appetite setting. We will consider the risks and opportunities in our strategic and financial planning process if such risks and opportunities are deemed to be material. After reviewing the environmental, social and climate-related risks and our performance in response to such risks each year, we may revise and alter our ESG strategies as appropriate.

氣候變化 (續)

策略 (續)

氣候相關風險及機會 (續)

鑑於我們的業務性質，據董事所知，氣候變化不會對我們的業務營運造成任何重大影響。如遇極端自然天氣，我們將積極響應當地政府的相關政策，除本集團提供的人壽保險外，還將制定應急計劃，確保員工安全。對於極端天氣事件造成的實體風險，例如對資產的直接損害和供應鏈中斷的間接影響，我們將制定相應的應急和備災計劃，我們相信我們有能力應對氣候危機。於報告期間，我們的業務營運、策略或財務表現並無因環境、社會和氣候相關問題而受到任何重大影響。

本集團將每年至少進行一次企業風險評估，以涵蓋本集團面臨的當前和潛在風險，包括但不限於ESG層面的風險以及圍繞氣候變化等破壞性力量的策略風險。董事會將評估或聘請外部專家評估風險，並審閱本集團現有的策略、目標和內部控制，並實施必要的改進措施以降低風險。董事會、審核委員會、EHS經理和ESG工作小組將持續監督本集團的風險管理方法，包括氣候相關風險和在既定的營運流程進行風險管理，通過定期管理審查以採取適當的緩解措施。

降低、轉移、接受或控制風險的決策受到政府監管、節能供應情況等多種因素的影響。我們將把氣候相關議題，包括實體風險及轉型風險的分析，納入風險評估流程及風險偏好設定。倘該等風險及機遇被視為重大，我們將在策略及財務規劃過程中考慮該等風險及機遇。在每年檢討環境、社會和氣候相關風險以及我們應對此類風險的表現後，我們可能會酌情修訂及更改ESG策略。

CLIMATE CHANGE (continued)

Strategy (continued)

Business model and value chain

During the financial year, the Group conducted a structured assessment of the potential impact of the climate-related risks and opportunities identified above on its business model and value chain. Based on the assessment results, these climate-related factors do not currently have a material effect on the Group's operations, supported by the effectiveness of its existing risk mitigation measures. As climate risk management continues to evolve, the Group will proactively adopt scenario analysis in the coming period to enhance its capability to identify and evaluate emerging climate-related risks and their potential long-term implications for the business.

Strategy and decision-making

Cloudbreak's sustainability strategy is integral to our mission of developing novel ophthalmic therapies. We believe that long-term success depends not only on scientific innovation but also on our responsibility towards the environment, our people, and the communities we serve. Our strategy provides the framework to manage ESG risks, seize opportunities, and build a resilient, ethical, and sustainable business.

To translate our commitment into action, we have established a strategic framework built on four key pillars that guide our operations and decision-making:

1. **Environmental Stewardship:** Minimising our ecological footprint through responsible resource management and proactive climate action across our R&D and pilot production activities.
2. **People & Culture:** Fostering a safe, inclusive, and thriving workplace where every employee is valued, protected, and empowered to grow.

氣候變化 (續)

策略 (續)

業務模式及價值鏈

於本財政年度，本集團對上述識別出與氣候相關的風險及機會，對其業務模式及價值鏈產生的潛在影響進行系統評估。根據評估結果，在現有風險緩解措施有效運作的支持下，該等氣候相關因素目前並未對本集團的運營產生重大影響。隨著氣候風險管理不斷發展，本集團將在未來期間積極採用情景分析，以增強其識別及評估新出現氣候相關風險及其對業務潛在長期影響的能力。

策略及決策

撥康視雲的可持續發展策略為致力於開發新型眼科療法使命的重要組成部分。我們認為，長期成功不僅取決於科學創新，亦取決於我們對環境、員工以及所服務社區的責任。我們的策略為管理ESG風險、把握機遇以及構建具有抵禦力、道德且可持續發展的業務提供框架。

為將我們的承諾轉化為行動，我們建立一個基於四大關鍵支柱的策略框架，指導我們的營運及決策：

1. **環境監管：**通過在研發及試點生產活動中進行負責任的資源管理及積極的氣候行動，將我們的生態足跡降至最低。
2. **人員及文化：**營造安全、包容且充滿活力的工作場所，讓每位員工都受到重視、保護，並獲得成長賦能。

環境監管及管理

Environmental Stewardship & Management

CLIMATE CHANGE (continued)

Strategy (continued)

Strategy and decision-making (continued)

- Responsible Innovation & Quality:** Upholding the highest standards of ethics, safety, and quality in our research, clinical trials, and future product commercialisation.
- Accountable Governance:** Maintaining robust, transparent governance structures to ensure effective oversight, compliance, and ethical conduct throughout our operations.

This framework is overseen by our Board and implemented through our dedicated four-tier management structure (the Board, EHS Manager, ESG Working Group, EHS Team), ensuring accountability and continuous improvement.

The table below outlines our strategic focus areas within each pillar, linking our commitments to the foundational actions and management approach derived from our operations.

氣候變化 (續)

策略 (續)

策略及決策 (續)

- 負責任的創新及質量：**在研究、臨床試驗及未來產品的商業化過程中，始終堅守最高道德、安全及質量標準。
- 問責制管治：**建立穩固、透明的管治架構，以確保在我們的營運中實現有效監督、合規及道德規範。

該框架由我們的董事會監督，並通過我們專門的四級管理架構(董事會、EHS經理、ESG工作小組、EHS團隊)實施，從而確保問責制及持續改進。

下表概述每個支柱下的策略重點領域，將我們的承諾與從營運中得出的基礎行動及管理方法相連結。

Strategic Pillar 策略支柱	Key Priorities & Commitments 關鍵優先事項及承諾	Our Strategic Approach 我們的策略方法
Environmental Stewardship 環境監管	<ul style="list-style-type: none"> Climate Risk Management Resource Efficiency 	<ul style="list-style-type: none"> Systematically identify and manage climate-related risks and opportunities. Continuously improve the efficiency of energy, water, and material use in our operations. Strengthen the management of chemical safety and waste throughout its lifecycle.
People Well-being 員工福祉	<ul style="list-style-type: none"> Occupational Health & Safety Training & Development 	<ul style="list-style-type: none"> 系統性地識別及管理氣候相關風險及機會。 持續提高我們營運中的能源、水及材料使用效率。 在其整個週期內加強化學品安全及廢棄物管理。
	<ul style="list-style-type: none"> Occupational Health & Safety Training & Development 	<ul style="list-style-type: none"> Cultivate a robust safety culture to protect the well-being of all employees. Invest in continuous learning and professional growth for our teams.
	<ul style="list-style-type: none"> 職業健康與安全 培訓及發展 	<ul style="list-style-type: none"> 培養強大的安全文化，以保護所有員工的福祉。 為我們的團隊投資持續學習及專業發展。

CLIMATE CHANGE (continued)

氣候變化 (續)

Strategy (continued)

策略 (續)

Strategy and decision-making (continued)

策略及決策 (續)

Strategic Pillar 策略支柱	Key Priorities & Commitments 關鍵優先事項及承諾	Our Strategic Approach 我們的策略方法
Operational Excellence 卓越營運	<ul style="list-style-type: none"> Clinical Trial Patient Safety & Ethics 臨床試驗患者安全及倫理 	<ul style="list-style-type: none"> Ensure the highest standards of patient safety, ethical conduct, and data integrity in all clinical research. Embed quality and sustainability considerations into our R&D processes. 在所有臨床研究中確保最高標準的患者安全、倫理行為及數據完整性。 將質量及可持續發展考慮因素納入我們的研發流程。
Responsible Governance 負責任的管治	<ul style="list-style-type: none"> ESG Oversight & Disclosure Compliance & Risk Control Anti-corruption ESG監督及披露 合規及風險控制 反貪污 	<ul style="list-style-type: none"> Maintain rigorous oversight of ESG performance and ensure transparent communication with stakeholders. Uphold the highest standards of legal compliance and ethical business conduct. 維持對ESG績效的嚴格監督，並確保與持份者保持透明溝通。 遵守最高法律合規及商業道德標準。

Financial position, financial performance and cash flows

財務狀況、財務表現及現金流量

The Group recognises that climate-related risks and opportunities may affect its current and future financial performance, cash flows and overall financial position.

本集團認識到氣候相關風險及機會可能影響其當前及未來的財務表現、現金流量及整體財務狀況。

- Current financial effect: During the financial year, the Group assessed the existing financial impacts arising from the climate-related issues identified. As a clinical-stage ophthalmology biotechnology company primarily engaged in drug discovery and research and development activities, the Group is still at an early stage of business development. Given the nature and scale of its current operations, climate-related factors did not give rise to any material financial impact on the Group during the reporting period.

- 當前財務影響：於財政年度，本集團對已識別的氣候相關問題所產生的一系列現有財務影響進行評估。作為一間主要從事藥物探索及研發活動的臨床階段眼科生物技術公司，本集團目前仍處於業務發展的早期階段。鑑於其當前業務的性質及規模，氣候相關因素於報告期間並未對本集團造成任何重大財務影響。

環境監管及管理

Environmental Stewardship & Management

CLIMATE CHANGE (continued)

Strategy (continued)

Financial position, financial performance and cash flows (continued)

- The Group has assessed the potential impact of climate-related risks and opportunities on its financial position, including investment and disposal plans, as well as sources of funding. Given that climate-related financial impacts involve significant assumptions and forward-looking information, and the Group is currently in a critical transition period from clinical-stage to commercialization, the relevant investment plans and funding sources have not yet been finalized. Therefore, the Group temporarily refrains from disclosing specific expectations regarding its financial position. The Group will continue to assess climate-related issues and provide supplementary disclosures in future reporting periods as appropriate.
- The Group expects that climate-related factors will have a positive impact on its financial performance and cash flows in the medium to long term, primarily driven by the potential increase in demand for its core product, CBT-001. As global climate change intensifies, atmospheric conditions deteriorate, and sunlight exposure expands, the risk of ultraviolet-related diseases (such as pterygium) is expected to rise. Currently, there are no approved drug therapies for pterygium worldwide, and existing treatment options (surgery and pharmacotherapy) have significant limitations. As a potential first-in-class drug, CBT-001 offers notable clinical advantages and substantial market potential.
- In the short term, the Group will remain in the clinical R&D stage, with R&D expenditures maintaining at a relatively high level, which may exert pressure on current profitability and operating cash flow. As the clinical progress of CBT-001 advances and commercialization preparations proceed, sales revenue is expected to gradually increase in the medium to long term, leading to improved operating performance. Operating cash flow is anticipated to turn positive in the medium term. In the long term, with increased product market penetration and expanded indications, the Group expects its revenue scale to continue growing, further enhancing profitability and cash flow levels.

Climate resilience

The Group acknowledges the significance of evaluating the climate resilience of its business strategy and business model in relation to climate-related changes, developments and uncertainties, by focusing on the climate-related risks and opportunities identified above. Following assessment, the Group considers that there are currently no significant areas of uncertainty that would materially impact its climate resilience.

氣候變化 (續)

策略 (續)

財務狀況、財務表現及現金流量 (續)

- 本集團已評估氣候相關風險與機遇對財務狀況的潛在影響，包括投資及處置計劃、資金來源等方面。鑒於氣候相關財務影響涉及較多假設及前瞻性信息，且本集團目前正處於臨床階段向商業化過渡的關鍵時期，相關投資計劃及資金來源尚未最終確定，暫不披露具體財務狀況預期。本集團將持續評估氣候相關議題，並在未來報告期適時補充披露。
- 本集團預計氣候相關因素將在中長期內對其財務業績及現金流量產生正面影響，主要得益於核心產品CBT-001的潛在需求增長。隨著全球氣候變化加劇、大氣狀況惡化及日照範圍擴大，紫外線暴露相關疾病(如翼狀胬肉)的患病風險預計將持續上升。目前全球尚無獲批的翼狀胬肉藥物療法，現有治療手段(手術及藥物治療)存在明顯局限，而CBT-001作為潛在首創藥物，具有顯著的臨床優勢及市場潛力。
- 在短期，本集團仍將處於臨床研發階段，研發支出維持較高水平，可能對當期盈利能力及經營現金流產生一定壓力。隨著CBT-001臨床進展及商業化準備推進，預計在中長期逐步實現銷售收入增長，帶動經營業績改善，經營性現金流量預計將在中期內轉為正數。長期而言，隨著產品市場滲透率提升及適應症拓展，本集團預期收入規模持續擴大，盈利能力和現金流水平將進一步增強。

氣候韌性

本集團認識到，評估其業務策略及業務模式在應對氣候相關變化、發展及不確定性方面的氣候韌性的重要性，並專注於上述識別的氣候相關風險及機會。經評估，本集團認為目前並無對其氣候韌性構成重大影響的不確定因素範疇。

CLIMATE CHANGE (continued)

Risk Management

Climate-related risks are integrated into our enterprise risk management framework. This framework operates under guidelines approved by the Board, ensuring that key corporate risks are systematically identified, assessed, managed and monitored, and is applied consistently across all risk categories, including climate-related physical and transition risks.

In identifying and assessing climate-related risks, we draw on diverse information sources, including government-issued meteorological and disaster data, industry risk research reports, and internal operational information. The scope of assessment covers the Group's owned R&D and office facilities, and extends to key supply chain segments. The Group considers the nature of risks (e.g., impacts on personnel safety, asset integrity, operational continuity, compliance costs and financial performance), likelihood of occurrence, and potential magnitude of impact, supplemented by management's professional judgement through qualitative assessment. The Group has not yet formally adopted climate scenario analysis for risk identification, but plans to conduct pilot scenario analysis in the future to enhance its understanding of medium- to long-term climate-related risks in the future.

Monitoring of climate-related risks is conducted through annual enterprise risk assessments and regular management review mechanisms. The Board and the ESG Working Group periodically review the progress of corresponding mitigation measures, while EHS Manager monitors the implementation of specific remedial actions.

The processes described above for identifying, assessing, and monitoring climate-related risks and opportunities are fully integrated into the Group's unified enterprise risk management framework. This framework is ultimately overseen by the Board, with risk management functions and the ESG Working Group operating in coordination to ensure that climate considerations are appropriately taken into account in major decisions, strategic planning, and resource allocation.

Metrics and Targets

As a clinical-stage biotechnology company focused on ophthalmology drug discovery and development, the Group does not plan to operate manufacturing plants, heavy industrial facilities, or other activities that typically generate direct greenhouse gas emissions. Our operations are primarily research and development, and administrative in nature, based in laboratory and office environments in the United States and China.

氣候變化 (續)

風險管理

氣候相關風險已被納入企業風險管理框架。該框架根據董事會批准的指引運作，確保關鍵企業風險得到系統識別、評估、管理及監控，並且在所有風險類別(包括與氣候相關的實體風險和轉型風險)中一致應用。

於識別及評估氣候相關風險時，我們已參考多種資料來源，包括政府發佈的氣象及災害數據、行業風險研究報告及內部運營資料。評估範圍涵蓋本集團擁有的研發及辦公設施，並延伸至關鍵供應鏈環節。本集團會考慮風險的性質(例如對人員安全、資產完整性、運營持續性、合規成本及財務表現的影響)、發生的可能性及潛在影響程度，並以管理層通過定性評估得出的專業判斷作為補充。本集團尚未正式採用氣候情景分析來進行風險識別，但計劃於未來開展試點情景分析，以增強其對未來中長期氣候相關風險的了解。

氣候相關風險的監控通過年度企業風險評估及定期管理審查機制進行。董事會及ESG工作小組定期檢討相應緩解措施的進展情況，而EHS經理則負責監督具體補救措施的實施情況。

上述用於識別、評估及監控氣候相關風險及機會的流程已完全融入本集團統一的企業風險管理框架。該框架最終由董事會監督，風險管理職能部門及ESG工作小組協同運作，以確保在重大決策、策略規劃及資源配置中適當考慮氣候因素。

指標及目標

作為一間專注於眼科藥物研發的臨床階段生物技術公司，本集團暫不經營生產工廠、重工業設施或通常會產生直接溫室氣體排放的其他活動。我們的業務主要為研究及開發和行政管理性質，工作地點位於美國及中國的實驗室及辦公環境。

環境監管及管理

Environmental Stewardship & Management

CLIMATE CHANGE (continued)

Metrics and Targets (continued)

Given this business model, the Group does not produce material Scope 1 emissions (direct emissions from owned or controlled sources such as fuel combustion or industrial processes). Accordingly, our carbon footprint is primarily associated with Scope 2 emissions (purchased electricity) and Scope 3 emissions (upstream and downstream activities).

氣候變化 (續)

指標及目標 (續)

鑑於該業務模式，本集團不產生實質的範圍1排放(來自自有或控制來源的直接排放，例如燃料燃燒或工業生產過程)。因此，我們的碳足跡主要與範圍2(購買電力)及範圍3排放(上游及下游活動)相關。



- 1: 2025 Scope 3 emissions include category 6 Business Travel and category 7 Employee Commute. They have been calculated based on GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard.
2025年範圍3排放量包括第6類商務旅行及第7類員工通勤。這些排放量是根據《溫室氣體核算體系：企業價值鏈(範圍3)核算與報告標準》計算得出。
- 2: 2025 Scope 2 market-based emissions refer to the indirect GHG emissions from the generation of purchased or acquired electricity consumed by Cloudbreak. These emissions were calculated based on the emission factors adopted by Cloudbreak, including the China mainland regional average grid emission factor published by the Ministry of Ecology and Environment (MEE) (0.5306 kg CO₂e/kWh), Power Assets emission factor (0.600 kg CO₂e/kWh), the CLP Group emission factor (0.3800 kg CO₂e/kWh), and the USA emission factor published by the U.S. Environmental Protection Agency (EPA) (0.3517 kg CO₂e/kWh).
2025年範圍2市場基礎排放量指撥康視雲所消耗的購買或獲取電力產生之間接溫室氣體排放。這些排放量是根據撥康視雲採用的排放係數計算得出，包括：中華人民共和國生態環境部(MEE)發佈的中國大陸區域平均電網排放因子(0.5306千克二氧化碳當量/千瓦時)，電力資產的排放因子(0.600千克二氧化碳當量/千瓦時)，中電集團(CLP Group)的排放因子(0.3800千克二氧化碳當量/千瓦時)，以及美國環境保護署(EPA)發佈的排放因子(0.3517千克二氧化碳當量/千瓦時)。

CLIMATE CHANGE (continued)

氣候變化 (續)

Metrics and Targets (continued)

指標及目標 (續)

	2025
Scope 2 GHG Emission (tCO ₂ e) 範圍2溫室氣體排放量 (噸二氧化碳當量)	76.58
Scope 2 GHG Emission Intensity (tCO ₂ e/employee) 範圍2溫室氣體排放密度 (噸二氧化碳當量/僱員)	1.28
Scope 3 GHG Emission (tCO ₂ e) 範圍3溫室氣體排放量 (噸二氧化碳當量)	456.48
Scope 3 GHG Emission Intensity (tCO ₂ e/employee) 範圍3溫室氣體排放密度 (噸二氧化碳當量/僱員)	7.61
Total GHG Emission (tCO ₂ e) 溫室氣體排放總量 (噸二氧化碳當量)	533.06
Total GHG Emission Intensity (tCO ₂ e/employee) 溫室氣體排放總密度 (噸二氧化碳當量/僱員)	8.88

As the Group's business expands in the future, we will continue to strengthen our environmental management practices and broaden the scope of our disclosures. With the anticipated commercialisation of our products in the coming years, we recognise that new operational activities may introduce additional environmental impacts and responsibilities. The Group is committed to proactively addressing these developments by refining our carbon reduction targets, enhancing resource efficiency, and ensuring that our sustainability framework evolves in step with our business growth.

隨著本集團業務的持續拓展，我們將不斷強化環境管理實踐並擴大披露範圍。隨著產品預計於未來數年內商業化，我們意識到新增運營活動可能帶來額外的環境影響及責任。本集團致力於通過完善減碳目標、提高資源利用效率，以及確保可持續發展框架與業務增長同步發展，從而積極應對有關發展態勢。

RESOURCE STEWARDSHIP & CIRCULARITY

資源管理與循環發展

Cloudbreak is committed to the responsible stewardship of natural resources and the advancement of circular economy principles across our research and development operations. This commitment is formalised through established policies embedded within our environmental management system, including a formal Environmental Management System plan and specific management measures for hazardous chemical substances and waste. We recognise that our scientific activities, while focused on innovation, carry an environmental footprint primarily through the consumption of energy and water, as well as the generation of waste. Our management approach is built on a foundation of systematic monitoring, continuous efficiency improvement, and stringent compliance. We aim to minimise our environmental impact by implementing conservation measures, optimising processes, and ensuring the safe, responsible handling of all materials throughout their lifecycle.

撥康視雲致力於負責任的自然資源管理，並在研發營運中推進循環經濟原則。我們透過環境管理系統中的既定政策落實該項承諾，包括正式的環境管理系統計劃及針對危險化學物質及廢棄物的具體管理措施。我們認識到，儘管科研活動側重於創新，但其主要通過能源及水資源消耗，以及產生廢棄物形成環境足跡。我們的管理方法建立在系統監控、持續效率提升及嚴格合規的基礎上。我們旨在透過實施保護措施、優化流程、以及確保所有材料於其週期內均獲得安全、負責任的處理，從而將對環境的影響降至最低。

環境監管及管理

Environmental Stewardship & Management

RESOURCE STEWARDSHIP & CIRCULARITY (continued)

Energy Management

Energy efficiency is a cornerstone of our environmental strategy. We have established a robust system for monitoring our electricity consumption, which provides a clear baseline for measuring performance and guiding our reduction initiatives. We have set a specific target to enhance our energy use efficiency: to reduce electricity consumption per employee by 2% by the end of 2027, compared to a 2025 baseline.

Our historical consumption data reflects the growth and intensification of our R&D activities:

	2023	2024	2025
Electricity Consumption (kWh) 耗電量(千瓦時)	400,000	840,000	866,769
Electricity Consumption Intensity (kWh/employee) 耗電密度(千瓦時/僱員)	10,256	19,091	14,446

To manage and reduce our energy footprint, we have implemented a series of operational measures, including:

- Promoting the purchase and use of energy-efficient lighting, office equipment, and laboratory appliances.
- Enforcing clear protocols to ensure all lights, air conditioning units, and non-essential equipment are switched off when facilities are unoccupied, supplemented by automated sensors where practical.
- Conducting regular inspections and preventive maintenance on all major equipment to ensure optimal, energy-efficient operation.
- Encouraging virtual meetings and conferences to reduce emissions associated with business travel.

Looking ahead, our strategy involves evaluating and integrating cleaner energy sources where feasible and investing in further energy-saving technologies, such as high-efficiency power systems, to decouple our energy consumption from our operational growth.

資源管理與循環發展(續)

能源管理

能源效率是我們環境策略的基石。我們已建立一套完善的耗電監控系統，為衡量績效及指導減排舉措提供明確的基準。我們設定一個具體目標提高能源利用率：到2027年底，與2025年基線相比，每位員工的耗電量減少2%。

我們的歷史消耗資料反映研發活動的增長和加強：

為管理和降低能源足跡，我們已採取一系列運營措施，包括：

- 推廣採購及使用節能照明設備、辦公設備及實驗室儀器。
- 實施明確的規範，確保在設施無人使用時，關閉所有照明、空調及非必要設備，並在可行情況下以自動感應裝置作輔助。
- 定期對所有主要設備進行檢查及預防性維護，以確保其以最佳的節能狀態運行。
- 鼓勵採用虛擬會議和研討會，以減少與商務差旅相關的排放。

展望未來，我們的策略包括在可行的情況下評估並整合更清潔能源，並進一步投資節能技術，例如高效電力系統，以實現能源消耗與業務增長脫鉤發展。

RESOURCE STEWARDSHIP & CIRCULARITY (continued)

資源管理與循環發展 (續)

Water & Effluent Management

水及污水管理

Responsible water stewardship is critical to our operations, particularly in supporting laboratory processes and facility hygiene. We actively monitor our water usage to understand consumption patterns and drive conservation efforts. Our water use is primarily attributed to laboratory operations and daily facility functions. We have established a target to improve water use efficiency by reducing consumption per employee by 2% by the end of 2027, against a 2025 baseline.

負責任的水資源管理對於我們的營運至關重要，尤其是在支援實驗室流程及設施衛生方面。我們積極監測用水情況，以了解耗水模式並推動節水工作。我們的用水主要來自實驗室營運及日常設施運作。我們已設定目標，計劃到2027年底，與2025年基線相比，將每位員工的耗水量減少2%，從而提高用水效率。

Our monitored consumption levels are as follows:

我們監控的耗水情況如下：

	2023	2024	2025
Water Consumption (Tons) 耗水量(噸)	292.09	355.02	680.18
Water Consumption Intensity (Tons/employee) 耗水密度(噸/僱員)	7.49	8.07	11.33

We foster a culture of water conservation through targeted initiatives, such as awareness campaigns and prominently displayed conservation reminders in our facilities. We encourage all employees to adopt water-saving practices in their daily work routines. Compliance is ensured through periodic environmental evaluations that assess wastewater detection and emissions, guaranteeing adherence to all applicable regulations. Future efforts will focus on exploring advanced water recycling technologies and process innovations to reduce the intensity of our water use as our operations scale.

我們通過有針對性的舉措來培養節水文化，例如開展宣傳活動以及在設施內顯眼位置張貼節水提示。我們鼓勵所有僱員在日常工作中採用節水措施。通過定期的環境評估來確保合規性，評估廢水檢測及排放情況，以確保遵守所有適用法規。隨著業務規模的擴大，未來工作將著重於探索先進的水循環技術及工藝創新，以降低用水密度。

環境監管及管理

Environmental Stewardship & Management

RESOURCE STEWARDSHIP & CIRCULARITY (continued)

Waste & Materials Management

The safe and environmentally sound management of waste, especially hazardous laboratory waste, is a paramount responsibility. We adhere to a strict hierarchy of waste management: prioritising reduction at source, ensuring safe handling, and guaranteeing final disposal through fully compliant channels. To drive continuous improvement, we have set a target to reduce hazardous waste generation per employee by 2% by the end of 2027, using 2025 as our baseline.

We track and manage our waste streams:

	2023	2024	2025
Hazardous Waste Discharge (Tons) 有害廢棄物排放(噸)	4.19	10.63	9.99
Hazardous Waste Discharge Intensity (Tons/employee) 有害廢棄物排放密度(噸/僱員)	0.11	0.24	0.17
Non-hazardous Waste Generated (Tons) 產生的無害廢棄物(噸)	NA ³	NA ³ 不適用 ³	4.71
Non-hazardous Waste Intensity (Tons/employee) 無害廢棄物密度(噸/僱員)	NA ³ 不適用 ³	NA ³ 不適用 ³	0.08
Total Waste Generated (Tons) 產生的廢棄物總量(噸)	4.19	10.63	14.71
Total Waste Intensity (Tons/employee) 廢棄物總密度(噸/僱員)	0.11	0.24	0.25

All Hazardous waste is consigned to qualified, licensed third-party processors for treatment and disposal.

As for general and recyclable waste, we operate a comprehensive, color-coded segregation system for non-hazardous waste, including disqualified product/packaging, hard plastics, general waste, solvent-soaked items, and recyclable paper/cardboard, ensuring each stream follows the correct disposal or recycling pathway.

3: Data on non-hazardous waste were not collected in FY23 and FY24. 在FY23和FY24期間，集團未有收集無害廢物相關數據

資源管理與循環發展(續)

廢棄物及材料管理

廢棄物(尤其是危險實驗室廢棄物)的安全與環保管理是一項至關重要的責任。我們嚴格遵循廢棄物管理層級：優先從源頭減少廢棄物，確保安全處理，並通過完全合規的渠道進行最終處置。為推動持續改進，我們已設定一個目標，到2027年底，與2025年基線相比，將每位員工產生的危險廢棄物減少2%。

我們對廢棄物流進行跟蹤及管理：

所有危險廢物均委託給具備資質、有執照的第三方處理商進行處理和處置。

對於一般及可回收廢棄物，我們採用全面的顏色編碼分類系統對無害廢棄物進行分類，包括不合格的產品/包裝、硬質塑膠、一般廢棄物、溶劑浸漬物品以及可回收的紙張/紙板，確保每類廢物均遵循正確的處置或回收路徑。

RESOURCE STEWARDSHIP & CIRCULARITY *(continued)*

Waste & Materials Management *(continued)*

Our management system is reinforced by concrete actions:

- **Source Reduction:** We regularly audit our R&D processes to identify and implement opportunities for waste minimisation.
- **Enhanced Treatment:** We are investing in on-site pre-treatment capabilities to reduce the hazard potential of waste before off-site disposal.
- **Operational Rigor:** Our procedures enforce strict compliance with GMP standards and pollutant emission regulations, backed by regular audits.

Our forward-looking plans include investing in advanced treatment systems, expanding material recycling schemes, and establishing centralised, standardised storage for hazardous materials to build a more resilient and circular waste management ecosystem for the future.

資源管理與循環發展 *(續)*

廢棄物及材料管理 *(續)*

我們的管理系統透過具體行動得到加強：

- **源頭減量：**我們定期審查研發流程，以識別並實施減廢棄物產生的機會。
- **強化處理：**我們正在投資建設現場預處理設施，以降低廢棄物在場外處置前的潛在危害。
- **嚴格的營運：**我們的流程嚴格執行 GMP 標準及污染物排放規定，並定期接受審核。

我們的前瞻性計劃包括投資先進的處理系統、擴大材料回收計劃以及建立集中、標準化的危險材料儲存設施，以建立一個更具韌性及循環的未來廢棄物管理生態系統。

LABOUR STANDARDS

Corporate social responsibility is integral to our core growth philosophy and is pivotal to creating sustainable, long-term value for our Stakeholders. We are committed to upholding the highest standards of fairness, respect, and dignity for every individual within our organisation. This commitment is operationalised through strict adherence to all applicable labour laws and regulations in the jurisdictions where we operate, covering recruitment, promotion, compensation, working hours, rest periods, and termination. Our approach is grounded in the principle that a diverse, inclusive, and ethically managed workforce is fundamental to our innovation and success.

We hire employees based on merit and are dedicated to providing equal opportunities to all, regardless of gender, age, race, religion, or any other social or personal characteristics. We actively cultivate an inclusive culture where diverse perspectives are not only welcomed but are seen as essential to driving innovation and problem-solving. Our commitment extends beyond policy to everyday practice, fostering a sense of belonging where every employee can contribute authentically. As of 31 December 2025, approximately 55% of our total employees were female, reflecting our ongoing progress in building a representative workforce. We are always dedicated to fostering a workplace of equality where every employee is respected and committed to providing equal treatment in hiring, training, wellness, and professional development, empowering all to grow and realise their full potential.

Our ethical standards are rigorously upheld from the first point of contact with potential employees. We maintain strict recruitment practices, including the verification of original identity documents, to ensure transparency and integrity. We maintain a robust framework to ensure all working arrangements consistently meet or exceed the requirements of local labour laws and regulations in every jurisdiction we operate. This proactive compliance is part of our broader commitment to ethical management and social responsibility. Upon discovery of any incidents involving child labour or forced labour, we will immediately investigate, take prompt remedial action, and implement strengthened measures to eliminate and prevent such practices. We are also committed to engaging with customers, employees, business partners, governmental agencies, and other stakeholders to understand their needs and support community activities.

Moving forward, we will continue to evolve our practices and policies to meet the highest international standards of labour rights and employee welfare. Our goal is to be recognised not just for what we achieve scientifically, but for how we grow our team – with unwavering ethics, mutual respect, and a steadfast commitment to human dignity at every stage of the employment lifecycle.

勞工準則

企業社會責任是我們核心成長理念的重要組成部分，對於為持份者創造可持續、長期價值至關重要。我們致力於為組織內的每名成員維護最高標準的公平、尊重及尊嚴。我們透過嚴格遵守營運所在司法權區的所有適用勞工法律和法規來實現該承諾，涵蓋招聘、晉升、薪酬、工作時間、休息時間以及解僱等方面。我們的方針基於一項原則：多元、包容且遵循道德規範的勞工是我們的創新及成功的基礎。

我們秉持擇優錄用原則，致力於為所有人提供平等機會，無論其性別、年齡、種族、宗教或其他社會或個人特徵。我們積極培育包容的文化，不僅歡迎多元觀點，更視其為推動創新與解決問題的關鍵要素。我們的承諾不僅體現在政策層面，更延伸至日常實踐，營造歸屬感，讓每位員工都能真實貢獻所長。截至2025年12月31日，女性僱員佔總僱員比例為約55%，反映我們在構建具有代表性的員工隊伍方面取得的持續進展。我們始終致力於營造平等的工作環境，尊重每名員工，並在招聘、培訓、福祉及職業發展方面提供平等待遇，從而激勵所有員工成長並充分發揮自身潛力。

我們至與潛在員工初次接觸起便嚴格遵守道德標準。我們實施嚴格的招聘流程，包括核實身份證明文件原件，以確保透明度及誠信。我們亦建立完善的框架，以確保所有工作安排始終符合或超過營運所在司法權區的當地勞工法律和法規的要求。積極的合規是我們踐行道德管理與社會責任承諾的一部分。一經發現任何涉及童工或強迫勞動的情況，我們會立即展開調查、及時採取補救措施，並實施強化方案，以杜絕及預防有關行為。我們亦致力於與客戶、員工、業務夥伴、政府機構及其他持份者保持溝通，以理解其需求並支持社區活動。

展望未來，我們將繼續改進我們的實踐及政策，以符合國際勞動權利及員工福利的最高標準。我們的目標不僅在於取得科學成就而受到認可，更在於我們如何培養團隊而獲得認可 – 在僱傭週期的每個階段，我們均秉持堅定不移的道德準則、相互尊重以及對人類尊嚴的堅定承諾。

LABOUR STANDARDS (continued)

勞工準則 (續)

Human Capital Profile

人力資本概況

The Group 本集團	Number of Employees 員工數目	61
By Employment Type 按僱傭類別劃分	Permanent 永久	60
	Temporary 臨時	1
By Gender 按性別劃分	Male 男性	27
	Female 女性	34
By Employee Category 按僱員類別劃分	Senior management 高級管理層	6
	Middle management 中級管理層	18
	General Staff 普通員工	37
By Age Group 按年齡組別劃分	29 or Below 29歲或以下	9
	30-39 30至39歲	17
	40-49 40至49歲	14
	50-59 50至59歲	15
	60 or Above 60歲或以上	6
By Region 按區域劃分	Hong Kong 香港	15
	Mainland China 中國內地	33
	United States 美國	12
	Germany 德國	1

LABOUR STANDARDS (continued)

勞工準則 (續)

Employment Turnover Rate 員工流失率		
The Group 本集團	Number of Employees 員工數目	17%
By Gender 按性別劃分	Male 男性	22%
	Female 女性	12%
By Age Group 按年齡組別劃分	29 or Below 29歲或以下	33%
	30-39 30至39歲	24%
	40-49 40至49歲	7%
	50-59 50至59歲	7%
	60 or Above 60歲或以上	17%
	By Employee Category 按僱員類別劃分	Senior management 高級管理層
	Middle management 中級管理層	11%
	General Staff 普通員工	19%
By Geographical Region 按地理區域劃分	Hong Kong 香港	40%
	Mainland China 中國內地	3%
	United States 美國	17%
	Germany 德國	0%

OCCUPATIONAL HEALTH AND SAFETY

Providing a safe and healthy work environment is a fundamental commitment and a cornerstone of our operational integrity at Cloudbreak. We strive to operate all facilities in a manner that prioritises the physical and mental well-being of our employees above all else, recognising that a secure workplace is essential for innovation, productivity, and sustainable growth.

The Group strictly complies with all applicable occupational health and safety laws and regulations across our operations, including the Occupational Safety and Health Ordinance and other relevant local requirements. During the reporting period, we recorded no instances of non-compliance with relevant health and safety statutes or regulatory requirements.

職業健康與安全

為員工提供安全健康的工作環境是撥康視雲的基本承諾，亦是我們營運誠信的基石。我們致力於以優先保障僱員的身心健康為首要原則來營運所有設施，因為我們深知安全的工作場所對於創新、生產力及可持續發展至關重要。

本集團在所有營運活動中均嚴格遵守所有適用職業健康與安全法律法規，包括職業安全及健康條例及其他相關當地要求。於報告期間，我們並無錄得違反相關健康及安全法規或監管規定的事項。

OCCUPATIONAL HEALTH AND SAFETY (continued)

We have implemented a comprehensive framework to identify, assess, and address potential occupational risks. This system is designed to be proactive and preventive, embedding safety into every aspect of our operations. Core measures include the implementation of detailed work safety guidelines covering safe practices, accident prevention, and reporting procedures, with internal compliance closely monitored. We mandate that all employees operating specialised equipment hold the requisite certifications, ensuring technically competent handling. Furthermore, we conduct regular safety inspections of our laboratories and manufacturing facilities and have established clear procedures to manage any work safety incidents effectively.

Given that our research and development activities involve the use of hazardous materials, we maintain stringent, specialised safety protocols. These protocols provide clear guidelines for the entire lifecycle of hazardous materials – covering handling, use, storage, treatment, and disposal – as well as comprehensive emergency planning and response. Our approach to chemical safety is integrated and meticulous, aiming to mitigate risks at their sources through engineering controls, administrative measures, and continuous procedural refinement.

We believe that occupational health extends beyond accident prevention to encompass overall employee wellness. In addition to providing necessary personal protective equipment (“PPE”), we offer a range of health support initiatives. This includes providing occupational health check-ups for employees in contact with potentially toxic substances and supporting general employee wellness through initiatives such as annual health checks. We are committed to supporting the holistic health of our workforce through a supportive framework that addresses both preventive care and overall quality of life at work. Our benefits framework is designed to offer comprehensive support, which includes medical insurance coverage and practical provisions such as meals for staff working extended hours at designated offices and sites.

Our workplace safety performance reflects the effectiveness of these measures. During the reporting period, we recorded zero work-related injuries and zero lost workdays due to occupational injuries. Our commitment to occupational health and safety is dynamic and enduring. We are dedicated to the continuous review and enhancement of our systems, leveraging lessons learned, technological advancements, and employee feedback to reach ever-higher standards of workplace safety and health. This unwavering commitment ensures we not only protect our people but also build a resilient, responsible, and sustainable organisation.

職業健康與安全 (續)

我們已實施一套全面的框架，以識別、評估及解決潛在職業風險。該系統旨在採取積極主動的預防措施，將安全融入我們營運的各個層面。核心措施包括實施詳細的工作安全指引，包括安全操作規範、事故預防及報告程序，並密切監控內部合規情況。我們規定，所有操作專業設備的僱員均必須持有必要的證書，以確保具備相應技術操作能力。此外，我們會定期對實驗室及生產設施進行安全檢查，並制定明確的程序來有效管理任何工作安全事故。

鑑於研發活動涉及使用危險材料，我們制定嚴格專業的安全規程。這些規程為危險材料的整個週期提供明確的指引—包括處理、使用、儲存、處理及處置，以及全面的應急規劃及響應。我們採取全面縝密的化學品安全管理策略，旨在透過工程控制、行政措施及持續優化流程，從源頭降低風險。

我們認為，職業健康不僅包括預防事故，亦包括員工的整體福祉。除提供必要個人防護裝備(「PPE」)外，我們亦提供一系列健康支援計劃。這包括為接觸潛在有毒物質的僱員提供職業健康檢查，並透過年度健康檢查等舉措來支持員工的整體健康狀況。我們致力於通過支持性框架來保障員工的身心健康，該框架既涵蓋預防性保健，亦注重工作中的整體生活品質。福利框架旨在提供全面的支援，其中包括醫療保險及實際措施，例如為在指定辦公室及場所長時間工作的員工提供餐食。

我們的工作場所安全表現反映該等措施的有效性。於報告期間，我們錄得零工傷事故及因職業傷害導致零工時損失。我們對職業健康及安全的承諾持續且堅定。我們致力於持續審查及改進我們的系統，充分利用經驗教訓、技術進步及員工反饋，以達到更高的工作場所安全及健康標準。這份堅定不移的承諾確保我們不僅能保護員工，亦能建立具有韌性、負責任且可持續發展的組織。

DEVELOPMENT AND TRAINING

At Cloudbreak, we view continuous learning and professional growth as strategic imperatives that drive both individual potential and organisational excellence. We are committed to establishing a robust and layered training design system to ensure every employee receives appropriate and sufficient development opportunities aligned with their role and career aspirations.

Our approach to employee development is built on a structured framework designed to be both comprehensive and tailored. The EHS Manager holds responsibility for identifying specific training needs across different employee groups based on job functions, which forms the foundational training matrix. The EHS Coordinator then develops the internal training schedule from this matrix, ensuring timely and relevant delivery. This systematic process ensures our training investments are strategic, data-informed, and directly support both operational compliance and capability building. Execution and completion of training programs are supervised by respective area managers and team leaders, embedding accountability for development within our management structure. We deliver a range of training initiatives to support employees at all stages of their tenure and across all functions.

- **Induction for New Hires:** We provide comprehensive induction training for all new employees. This ensures they are equipped with the necessary awareness, technical know-how, and understanding of our corporate culture to perform their work safely and effectively from the outset.
- **Role-Specific and Ongoing Training:** We are dedicated to conducting trainings directly relevant to employees' current positions and evolving responsibilities. This includes the continuous training to enhance awareness of ESG issues and deepen the practical skills required for safety and operational standards, ensuring our teams remain compliant and proficient.
- **Specialised and Advanced Development:** Staff in specialised departments, such as manufacturing, quality control, and quality assurance, receive foundational and advanced training in their fields to maintain up-to-date expertise. Furthermore, we deliver specialised training to address specific organisational needs, such as post-IPO compliance training, ensuring our team navigates new regulatory landscapes effectively.

發展及培訓

在撥康視雲，我們認為持續學習及職業成長是推動個人潛能及組織卓越的戰略要務。我們致力於建立完善且多層次的培訓設計體系，以確保每位員工獲得與其崗位職責及職業願景相符的適當及充分的發展機會。

員工發展方法建立在結構化框架之上，該框架兼具全面性與定制化特徵。EHS經理負責根據崗位職能識別不同員工組別的特定培訓需求，從而形成基礎培訓矩陣。然後，EHS協調員根據該矩陣制定內部培訓計劃，確保培訓及時有效。該系統化流程確保培訓投資具有戰略性、基於數據，並直接支持營運合規及能力建設。培訓計劃的執行及完成由各區域經理及團隊負責人監督，將發展責任深植管理架構。我們提供一系列培訓計劃，以支持僱員在其任期各階段及跨職能領域的發展：

- **新進員工入職培訓：**我們為所有新進員工提供全面的入職培訓。這確保彼等從一開始便具備必要的認知、技術知識和對我們企業文化的理解，從而能夠安全有效地開展工作。
- **專業崗位及持續培訓：**我們致力於開展與員工當前職位及不斷變化的職責直接相關的培訓。其包括持續培訓，以增強對ESG議題的認識，並加深安全及營運標準所需的實用技能，確保我們的團隊始終合規且技術熟練。
- **專業及高級發展：**在製造、質量控制及質量保證等專業部門的員工會接受其領域的基礎及高級培訓，以保持其專業知識與時俱進。此外，我們亦會提供專門培訓，以滿足特定的組織需求，例如首次公開發售後的合規培訓，確保我們的團隊能夠有效地應對新的監管環境。

DEVELOPMENT AND TRAINING (continued)

發展及培訓(續)

Our structured commitment to employee development is demonstrated through targeted training programs. For example, in 2025, we engaged external legal experts to conduct mandatory “Information Disclosure and Insider Trading” training for all employees, ensuring post-IPO compliance. Simultaneously, specialised “Good Clinical Practice (GCP)” training was provided to R&D staff, upholding the highest standards in our clinical trials. These initiatives exemplify how our layered training system translates into practical, role-specific learning that builds a capable and compliant workforce aligned with our strategic goals.

我們通過有針對性的培訓計劃，展現出對員工發展的系統性承諾。例如，於2025年，我們聘請外部法律專家，為全體員工提供強制性「資訊披露與內幕交易」培訓，確保首次公開發售後合規。與此同時，我們為研發人員提供專門的「良好臨床規範」培訓，以確保臨床試驗始終秉持最高標準。該等措施展現我們多層次培訓體系如何轉化為實踐、針對崗位的學習，從而培養能夠勝任工作並合規的員工隊伍，以符合我們的戰略目標。



Average Training Hours
per Employee
每名僱員平均受訓時數

12.5 hours
12.5小時

Percentage of
Employees Trained
受訓僱員百分比

75%

Total Training Hours
Completed by Our Employees
僱員完成的總培訓時數

749.1 hours
749.1小時

Number of Employees Trained and
breakdown
受訓僱員人數及細分

The Group 本集團	Number of Employees Trained 受訓僱員人數	45
By Gender 按性別劃分	Male 男性	16
	Female 女性	29
By Employee Category 按僱員類別劃分	Senior management 高級管理層	5
	Middle management 中級管理層	7
	General Staff 普通員工	33

DEVELOPMENT AND TRAINING *(continued)*

發展及培訓(續)

Average Training Hours Completed

已完成的平均培訓時數

By Gender 按性別劃分	Male 男性	9.2
	Female 女性	15.2
By Employee Category 按僱員類別劃分	Senior management 高級管理層	5.9
	Middle management 中級管理層	4.4
	General Staff 普通員工	17.6

COMMUNITY IMPACT

Cloudbreak recognises that our responsibilities extend beyond the laboratory to the communities in which we operate and the wider society we serve. We are committed to being a thoughtful and engaged corporate citizen, understanding that our long-term success is intertwined with the well-being of our stakeholders. We believe in fostering meaningful connections and contributing positively to societal progress, aligning our specialised expertise with broader community needs.

As a biotechnology company focused on advancing human health, our community engagement naturally emphasises the sphere of public health in the long term. We are dedicated to exploring avenues through which our work and resources can support health awareness, education, and accessibility, contributing to the foundational health of communities. During the reporting period, the Company provided donations to support local community initiatives.

Furthermore, the Company encourages its employees to participate in community activities, valuing the initiative and personal commitment of our team members. We aim to cultivate a culture where corporate social responsibility is embraced collectively, supporting our employees in their voluntary efforts to make a positive local impact.

社區影響

撥康視雲認識到，我們的責任不僅限於實驗室，更延伸至我們營運所在社區以及我們所服務的更廣泛的社會。我們致力於成為有深度思維且積極參與的企業公民，深知我們的長期成功與持份者的福祉息息相關。我們堅信透過建立有意義的聯繫，將我們專業的知識與更廣泛的社區需求相結合，為社會進步做出積極貢獻。

作為一間致力於促進人類健康的生物技術公司，我們的社區參與長期以來自然側重於公共衛生領域。我們致力於探索各種途徑，利用我們工作及資源支持健康意識、教育及醫療可及性，從而為社區的健康奠定基礎。於報告期間，本公司提供捐款，以支持當地社區的倡議活動。

此外，本公司鼓勵僱員參與社區活動，重視團隊成員的主動性及個人承諾。我們致力於培養企業社會責任得到集體認同的文化，支持僱員自願為當地創造積極影響。

RESPONSIBLE SUPPLY CHAIN

Cloudbreak recognises that a responsible and resilient supply chain is critical to our operational integrity, product quality, and overall sustainability performance. We are committed to extending our environmental, social, and governance standards to our procurement practices, ensuring that our partners align with our core values and risk management expectations.

Our approach is rooted in the belief that collaborative, ethical partnerships are fundamental to building a sustainable value chain that supports our long-term vision. The Company implements a rigorous supplier selection process to ensure the competence and suitability of suppliers. The factors considered in this process include, but are not limited to, experience, reputation and the holding of relevant licenses.

For supplier evaluation, we have developed detailed requirements from a comprehensive business perspective that apply to all of our suppliers and encompass an assessment of services provided, technical parameters, quality certifications, and innovation capabilities, as well as each supplier's performance in legal compliance, safety, health, and environmental stewardship. We view supplier engagement as an ongoing process of mutual commitment to high standards. Beyond initial selection, we aim to foster transparent communication and encourage continuous improvement among our key partners, integrating sustainability criteria into our long-term procurement strategy. This diligent approach enables us to manage risks proactively, ensure supply continuity, and uphold our responsibility across the entire lifecycle of our research and development activities.

責任供應鏈

撥康視雲認識到，建立負責任且具韌性的供應鏈對保障營運完整性、產品質量及整體可持續發展績效至關重要。我們致力於將環境、社會及管治標準延伸至採購實踐，確保合作夥伴符合我們的核心價值觀及風險管理預期。

我們的方針根植於信念，協作且符合道德規範的夥伴關係是建立可持續發展價值鏈的基礎，而該價值鏈支持我們的長期願景。本公司實施嚴格的供應商甄選流程，以確保供應商的資格和適合性。該流程考慮的因素包括但不限於經驗、聲譽及持有相關牌照。

於供應商評估方面，我們已從全面的商業角度制訂詳細要求，有關要求適用於所有供應商，當中包括評估所提供的服務、技術能力、品質認證、創新能力，以及供應商在法律合規、安全、健康及環境管理方面的表現。我們將與供應商合作視為持續、相互承諾遵循高標準的過程。除初步甄選外，我們亦致力於促進主要合作夥伴之間的透明溝通，並鼓勵不斷改進，將可持續發展標準納入我們的長期採購策略。該嚴謹的方法使我們能夠主動管理風險，確保供應的持續性，並在研發活動的整個週期內履行我們的責任。

Suppliers by Geographical Region
按地域劃分的供應商

Region 地區		Numbers 數目
HK	香港	62
Mainland China	中國內地	138
Other countries/regions in Asia	亞洲其他國家／地區	3
Europe	歐洲	11
North America	北美	60
Oceania	大洋洲	3

CLINICAL TRIAL SAFETY

At Cloudbreak, patient safety and ethical integrity are the non-negotiable foundations of our research and development mission. We are committed to the discovery and development of ophthalmic therapies that are not only innovative and effective but also uphold the highest conceivable standards of safety for participants. This commitment permeates every stage of our clinical trial activities, from initial design through to execution and monitoring, ensuring the well-being of trial participants is always the paramount consideration.

Our approach is governed by a comprehensive framework of policies and procedures designed to ensure rigorous ethical and scientific standards. We ensure full compliance with all regulatory and ethical requirements, obtaining necessary approvals from competent authorities for all study protocols. Our processes for patient selection and enrolment are meticulously structured to safeguard participant welfare and scientific validity, operating under principles of transparency and respect for individual autonomy. This includes designing appropriate study criteria, securing voluntary and fully informed consent from all participants, and maintaining meticulous, confidential documentation throughout the trial lifecycle.

To actively manage and enhance safety, we have implemented a multi-faceted safety management system. This system involves continuous monitoring and analysis of safety data, prompt reporting of any adverse events to regulatory bodies, and the periodic review and refinement of our trial protocols and safety plans based on emerging data and updated guidelines. We foster a culture of proactive safety vigilance, empowering our teams and partners to identify and address potential risks swiftly and effectively. This commitment is further reinforced by our integrated ESG deviation reporting system, which ensures that any safety-related incidents are thoroughly documented, investigated, and lead to corrective actions that prevent recurrence.

Through this unwavering dedication to ethical conduct and participant safety, we aim to build lasting trust with patients, healthcare professionals, and regulators, ensuring that our pursuit of scientific advancement is always aligned with our fundamental responsibility to do no harm.

In view of the nature of our operations, the Group did not report any instances of product recalls related to safety or health concerns during the reporting year.

臨床試驗安全

在撥康視雲，患者安全及道德誠信是我們研發使命不可動搖的基石。我們致力於發現及開發不僅創新有效，更能夠為參與者提供最高安全性標準的眼科療法。該承諾貫穿臨床試驗的每一個階段，從初始設計到執行監測，確保試驗參與者的福祉始終是首要考慮因素。

我們的方法遵循全面的政策及流程框架，確保嚴格遵守道德及科學標準。我們確保完全遵守所有監管及道德要求，並就所有研究方案獲得相關主管機構的必要批准。患者篩選與入組流程經精心設計，在保障參與者福祉及科學有效性的同時，遵循透明及尊重個人自主權原則。具體包括設計適當的研究標準、確保所有參與者自願且完全知情同意，並在整個試驗週期保持嚴謹保密的文件記錄。

為積極管理及提升安全性，我們實施多方面的安全管理系統。該系統包括持續監控及分析安全數據，及時向監管機構報告任何不良事件，並根據新數據及經更新指引定期審閱及修訂我們的試驗方案和安全計劃。我們倡導積極主動的安全防範文化，賦予團隊及合作夥伴權力，使其能夠迅速有效地識別及解決潛在風險。有關承諾亦透過整合ESG偏差報告系統得到加強，該系統確保任何與安全相關的事件均會被詳盡記錄、調查，並採取糾正措施以防止再次發生。

通過對道德規範和參與者安全的堅定承諾，我們旨在與患者、醫療保健專業人員以及監管機構建立持久的信任，確保我們對科學進步的追求始終與我們不傷害他人的基本責任保持一致。

鑑於我們業務的性質，於報告年度內，本集團並無報告任何與安全或健康問題相關的產品召回事件。

DATA-SECURITY

The protection of personal data, particularly sensitive patient and clinical trial participant information, is a fundamental responsibility in our research operations. We have established internal protocols to ensure the confidentiality, integrity, and security of all personal data collected during our clinical development activities. These protocols govern the collection, access, storage, and sharing of participant information, requiring strict adherence to applicable data protection laws and regulations in all jurisdictions where we operate. All personnel handling such data are required to follow documented procedures and maintain confidentiality. We are committed to the continuous improvement of our data governance framework to safeguard stakeholder trust and meet evolving regulatory expectations.

Throughout the reporting year, the Group did not receive any complaints related to breaches of customer privacy, or any reported cases of data leakage, theft, or loss involving customer information.

ANTI-CORRUPTION

Cloudbreak is committed to upholding the highest standards of integrity, transparency, and ethical conduct across all our business activities. We maintain a zero-tolerance policy towards bribery, corruption, fraud, and any form of improper conduct. The Group strictly complies with all applicable anti-corruption laws and regulations in the jurisdictions where we operate, including the Prevention of Bribery Ordinance and other relevant legislation.

Our governance framework includes a Whistleblowing Policy, which is established and published on the Company's website. This policy provides clear and confidential channels for employees, business partners, and other stakeholders to report suspected misconduct or irregularities without fear of retaliation. All reports are properly investigated, and appropriate corrective actions are taken. To strengthen our anti-corruption culture, we conduct region-specific training tailored to local rules and regulatory requirements. These initiatives aim to raise awareness, reinforce ethical decision-making, and ensure that all employees understand their responsibilities.

During the reporting period, there was no concluded legal cases regarding corrupt practices brought against the Group.

數據安全

保護個人數據，特別是敏感的患者及臨床試驗參與者資料，是我們研究運營中的基本責任。我們已制定內部規程，確保在臨床開發活動中收集的所有個人數據的保密性、完整性及安全性。這些規程規定參與者資料的收集、訪問、存儲及共享，要求嚴格遵守我們在所有營運司法管轄區適用的數據保護法律法規。所有處理有關數據的人員均須遵循書面程序並保密。我們致力於不斷完善數據管治框架，以維護持份者的信任並滿足不斷變化的監管要求。

於報告年度內，本集團未收到任何涉及客戶私隱洩露的投訴，亦未收到任何涉及客戶資料洩露、盜竊或遺失的報告案件。

反貪污

撥康視雲致力於在所有業務活動中恪守最高標準的誠信、透明度和道德標準。我們對賄賂、貪污、欺詐及任何形式的不當行為採取零容忍政策。本集團嚴格遵守運營所在司法管轄區的所有適用反貪污法律法規，包括防止賄賂條例及其他相關法規。

我們的管治框架包含舉報政策，該政策已制定並公佈於本公司網站上。該政策為僱員、業務夥伴及其他持份者提供清晰且保密的渠道，使其能夠舉報涉嫌不當行為或違規行為，而不用擔心遭受報復。所有舉報均會得到妥善調查，並採取相應糾正措施。為加強反貪污文化，我們開展符合當地法規及監管要求的區域化專項培訓。該等舉措旨在提升員工認知、強化道德決策意識，確保全體僱員了解自身責任。

於報告期間，並無針對本集團提起與貪污相關的已結案的法律案件。

HKEX ESG REPORTING CODE CONTENT INDEX
香港交易所《環境、社會及管治報告守則》內容索引

“Comply or explain” Provisions 「不遵守就解釋」條文		
KPIs 關鍵績效指標	HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
A. Environmental A. 環境		
Aspect A1 層面A1	Emissions 排放物	
General Disclosure 一般披露	Information on: 有關廢氣排放、向水及土地的排污、有害及無害廢棄物的產生等的： (a) the policies; and (a) 政策；及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air emissions, discharges into water and land, and generation of hazardous and non-hazardous waste (b) 遵守對發行人有重大影響的相關法律及規例的資料。	METRICS AND TARGETS 指標及目標 RESOURCE STEWARDSHIP & CIRCULARITY 資源管理及循環發展
KPI A1.1 關鍵績效指標A1.1	The types of emissions and respective emissions data. 排放物種類及相關排放數據。	METRICS AND TARGETS 指標及目標 RESOURCE STEWARDSHIP & CIRCULARITY 資源管理及循環發展
KPI A1.3 關鍵績效指標A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility). 所產生有害廢棄物總量(以噸計算)及(如適用)密度(如以每產量單位、每項設施計算)。	WASTE & MATERIALS MANAGEMENT 廢棄物及材料管理
KPI A1.4 關鍵績效指標A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility). 所產生無害廢棄物總量(以噸計算)及(如適用)密度(如以每產量單位、每項設施計算)。	WASTE & MATERIALS MANAGEMENT 廢棄物及材料管理
KPI A1.5 關鍵績效指標A1.5	Description of emission target(s) set and steps taken to achieve them. 描述所訂立的排放量目標及為達到這些目標所採取的步驟。	RESOURCE STEWARDSHIP & CIRCULARITY 資源管理及循環發展
KPI A1.6 關鍵績效指標A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them. 描述處理有害及無害廢棄物的方法，及描述所訂立的減廢目標及為達到這些目標所採取的步驟。	WASTE & MATERIALS MANAGEMENT 廢棄物及材料管理

“Comply or explain” Provisions 「不遵守就解釋」條文		
KPIs 關鍵績效指標	HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
Aspects A2 層面A2	Use of Resources 資源使用	
General Disclosure 一般披露	Policies on the efficient use of resources, including energy, water and other raw materials. 有效使用資源(包括能源、水及其他原材料)的政策。	ENERGY MANAGEMENT 能源管理 WATER & EFFLUENT MANAGEMENT 水及污水管理
KPI A2.1 關鍵績效指標A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility). 按類型劃分的直接及／或間接能源(如電、氣或油)總耗量(以千個千瓦時計算)及密度(如以每產量單位、每項設施計算)。	ENERGY MANAGEMENT 能源管理
KPI A2.2 關鍵績效指標A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility). 總耗水量及密度(如以每產量單位、每項設施計算)。	WATER & EFFLUENT MANAGEMENT 水及污水管理
KPI A2.3 關鍵績效指標A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them. 描述所訂立的能源使用效益目標及為達到這些目標所採取的步驟。	ENERGY MANAGEMENT 能源管理
KPI A2.4 關鍵績效指標A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them. 描述求取適用水源上可有任何問題，以及所訂立的用水效益目標及為達到這些目標所採取的步驟。	WATER & EFFLUENT MANAGEMENT 水及污水管理
KPI A2.5 關鍵績效指標A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced. 製成品所用包裝材料的總量(以噸計算)及(如適用)每生產單位佔量。	NOT APPLICABLE 不適用
Aspect A3 層面A3	The Environment and Natural Resources 環境及天然資源	
General Disclosure 一般披露	Policies on minimising the issuer's significant impact on the environment and natural resources. 減低發行人對環境及天然資源造成重大影響的政策。	RESOURCE STEWARDSHIP & CIRCULARITY 資源管理與循環發展
KPI A3.1 關鍵績效指標A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them. 描述業務活動對環境及天然資源的重大影響及已採取管理有關影響的行動。	RESOURCE STEWARDSHIP & CIRCULARITY 資源管理與循環發展

“Comply or explain” Provisions 「不遵守就解釋」條文		
KPIs 關鍵績效指標	HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
B. Social B. 社會		
Employment and Labour Practices 僱傭及勞工常規		
Aspect B1 層面B1	Employment 僱傭	
General Disclosure 一般披露	Information on: 有關薪酬及解僱、招聘及晉升、工作時數、假期、平等機會、多元化、反歧視以及其他待遇及福利的： (a) the policies; and (a) 政策；及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, antidiscrimination, and other benefits and welfare. (b) 遵守對發行人有重大影響的相關法律及規例的資料。	LABOUR STANDARDS 勞工準則
KPI B1.1 關鍵績效指標B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region. 按性別、僱傭類型(如全職或兼職)、年齡組別及地區劃分的僱員總數。	LABOUR STANDARDS 勞工準則
KPI B1.2 關鍵績效指標B1.2	Employee turnover rate by gender, age group and geographical region. 按性別、年齡組別及地區劃分的僱員流失比率。	LABOUR STANDARDS 勞工準則
Aspect B2 層面B2:	Health and Safety 健康與安全	
General Disclosure 一般披露	Information on: 有關提供安全工作環境及保障僱員避免職業性危害的： (a) the policies; and (a) 政策；及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards. (b) 遵守對發行人有重大影響的相關法律及規例的資料。	OCCUPATIONAL HEALTH AND SAFETY 職業健康與安全
KPI B2.1 關鍵績效指標B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year. 過去三年(包括匯報年度)每年因工亡故的人數及比率。	OCCUPATIONAL HEALTH AND SAFETY 職業健康與安全

“Comply or explain” Provisions 「不遵守就解釋」條文		
KPIs 關鍵績效指標	HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
KPI B2.2 關鍵績效指標B2.2	Lost days due to work injury. 因工傷損失工作日數。	OCCUPATIONAL HEALTH AND SAFETY 職業健康與安全
KPI B2.3 關鍵績效指標B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored. 描述所採納的職業健康與安全措施，以及相關執行及監察方法。	OCCUPATIONAL HEALTH AND SAFETY 職業健康與安全
Aspect B3 層面B3	Development and Training 發展及培訓	
General Disclosure 一般披露	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities. 有關提升僱員履行工作職責的知識及技能的政策。描述培訓活動。	DEVELOPMENT AND TRAINING 發展及培訓
KPI B3.1 關鍵績效指標B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management). 按性別及僱員類別(如高級管理層、中級管理層等)劃分的受訓僱員百分比。	DEVELOPMENT AND TRAINING 發展及培訓
KPI B3.2 關鍵績效指標B3.2	The average training hours completed per employee by gender and employee category. 按性別及僱員類別劃分，每名僱員完成受訓的平均時數。	DEVELOPMENT AND TRAINING 發展及培訓
Aspect B4 層面B4	Labour Standards 勞工準則	
General Disclosure 一般披露	Information on: 有關防止童工或強制勞工的： (a) the policies; and (a) 政策；及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour. (b) 遵守對發行人有重大影響的相關法律及規例的資料。	LABOUR STANDARDS 勞工準則
KPI B4.1 關鍵績效指標B4.1	Description of measures to review employment practices to avoid child and forced labour. 描述檢討招聘慣例的措施以避免童工及強制勞工。	LABOUR STANDARDS 勞工準則
KPI B4.2 關鍵績效指標B4.2	Description of steps taken to eliminate such practices when discovered. 描述在發現違規情況時消除有關情況所採取的步驟。	LABOUR STANDARDS 勞工準則

“Comply or explain” Provisions 「不遵守就解釋」條文		
KPIs 關鍵績效指標	HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
Operating Practices 營運慣例		
Aspect B5 層面B5	Supply Chain Management 供應鏈管理	
General Disclosure 一般披露	Policies on managing environmental and social risks of the supply chain. 管理供應鏈的環境及社會風險政策。	RESPONSIBLE SUPPLY CHAIN 責任供應鏈
KPI B5.1 關鍵績效指標B5.1	Number of suppliers by geographical region. 按地區劃分的供應商數目。	RESPONSIBLE SUPPLY CHAIN 責任供應鏈
KPI B5.2 關鍵績效指標B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, how they are implemented and monitored. 描述有關聘用供應商的慣例，向其執行有關慣例的供應商數目、以及相關執行及監察方法。	RESPONSIBLE SUPPLY CHAIN 責任供應鏈
KPI B5.3 關鍵績效指標B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored. 描述有關識別供應鏈每個環節的環境及社會風險的慣例，以及相關執行及監察方法。	RESPONSIBLE SUPPLY CHAIN 責任供應鏈
KPI B5.4 關鍵績效指標B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored. 描述在揀選供應商時促使多用環保產品及服務的慣例，以及相關執行及監察方法。	RESPONSIBLE SUPPLY CHAIN 責任供應鏈
Aspect B6 層面B6	Product Responsibility 產品責任	
General Disclosure 一般披露	Information on: 有關所提供產品和服務的健康與安全、廣告、標籤及私隱事宜以及補救方法的： (a) the policies; and (a) 政策；及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress. (b) 遵守對發行人有重大影響的相關法律及規例的資料。	CLINICAL TRIAL SAFETY 臨床試驗安全
KPI B6.1 關鍵績效指標B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons. 已售或已運送產品總數中因安全與健康理由而須回收的百分比。	NOT APPLICABLE. 不適用。

“Comply or explain” Provisions 「不遵守就解釋」條文		
KPIs 關鍵績效指標	HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
KPI B6.2 關鍵績效指標B6.2	Number of products and service related complaints received and how they are dealt with. 接獲關於產品及服務的投訴數目以及應對方法。	NOT APPLICABLE. 不適用。
KPI B6.3 關鍵績效指標B6.3	Description of practices relating to observing and protecting intellectual property rights. 描述與維護及保障知識產權有關的慣例。	NOT APPLICABLE. 不適用。
KPI B6.4 關鍵績效指標B6.4	Description of quality assurance process and recall procedures. 描述質量檢定過程及產品回收程序。	NOT APPLICABLE. 不適用。
KPI B6.5 關鍵績效指標B6.5	Description of consumer data protection and privacy policies, how they are implemented and monitored. 描述消費者資料保障及私隱政策，以及相關執行及監察方法。	DATA-SECURITY 數據安全
Aspect B7 層面B7	Anti-corruption 反貪污	
General Disclosure 一般披露	Information on: 有關防止賄賂、勒索、欺詐及洗黑錢的： (a) the policies; and (a) 政策；及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering. (b) 遵守對發行人有重大影響的相關法律及規例的資料。	ANTI-CORRUPTION 反貪污
KPI B7.1 關鍵績效指標B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases. 於匯報期內對發行人或其僱員提出並已審結的貪污訴訟案件的數目及訴訟結果。	ANTI-CORRUPTION 反貪污
KPI B7.2 關鍵績效指標B7.2	Description of preventive measures and whistle-blowing procedures, how they are implemented and monitored. 描述防範措施及舉報程序，以及相關執行及監察方法。	ANTI-CORRUPTION 反貪污
KPI B7.3 關鍵績效指標B7.3	Description of anti-corruption training provided to directors and staff. 描述向董事及員工提供的反貪污培訓。	ANTI-CORRUPTION 反貪污

“Comply or explain” Provisions 「不遵守就解釋」條文		
KPIs 關鍵績效指標	HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
Community 社區		
Aspect B8 層面B8	Community Investment 社區投資	
General Disclosure 一般披露	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests. 有關以社區參與來了解營運所在社區需要和確保其業務活動會考慮社區利益的政策。	COMMUNITY IMPACT 社區影響
KPI B8.1 關鍵績效指標B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport). 專注貢獻範疇(如教育、環境事宜、勞工需求、健康、文化、體育)。	COMMUNITY IMPACT 社區影響
KPI B8.2 關鍵績效指標B8.2	Resources contributed (e.g. money or time) to the focus area. 在專注範疇所動用資源(如金錢或時間)。	COMMUNITY IMPACT 社區影響

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
(I) Governance (I) 管治	
19. An issuer shall disclose information about: 19. 發行人須披露有關以下方面的資料：	

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
<p>(a) the governance body(s) (which can include a board, committee or equivalent body charged with governance) or individual(s) responsible for oversight of climate-related risks and opportunities. Specifically, the issuer shall identify that body(s) or individual(s) and disclose information about:</p> <p>(a) 負責監督氣候相關風險和機遇的治理機構(可包括董事會、委員會或其他同等治理機構)或個人的資訊。具體而言, 發行人須指出有關機構或個人及披露以下資訊:</p> <p>(i) how the body(s) or individual(s) determines whether appropriate skills and competencies are available or will be developed to oversee strategies designed to respond to climate-related risks and opportunities;</p> <p>(i) 該機構或個人如何釐定當前或將來是否有適當的技能和勝任能力來監督應對氣候相關風險和機遇的策略;</p> <p>(ii) how and how often the body(s) or individual(s) is informed about climate-related risks and opportunities;</p> <p>(ii) 該機構或個人獲悉氣候相關風險和機遇的方式和頻率;</p> <p>(iii) how the body(s) or individual(s) takes into account climate-related risks and opportunities when overseeing the issuer's strategy, its decisions on major transactions, and its risk management processes and related policies, including whether the body(s) or individual(s) has considered trade-offs associated with those risks and opportunities;</p> <p>(iii) 該機構或個人在監督發行人的策略、重大交易決策和風險管理程序及相關政策的過程中, 如何考慮氣候相關風險和機遇, 包括該機構或個人是否有考慮與該等氣候相關風險和機遇相關的權衡評估;</p> <p>(iv) how the body(s) or individual(s) oversees the setting of, and monitors progress towards, targets related to climate-related risks and opportunities (see paragraphs 37 to 40), including whether and how related performance metrics are included in remuneration policies (see paragraph 35); and</p> <p>(iv) 該機構或個人如何監督有關氣候相關風險和機遇的目標制定並監察達標進度(見第37段至第40段), 包括是否將相關績效指標納入薪酬政策以及如何納入(見第35段); 及</p>	<p>GOVERNANCE 管治</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
<p>(b) management’s role in the governance processes, controls and procedures used to monitor, manage and oversee climate-related risks and opportunities, including information about:</p> <p>(b) 管理層在用以監察、管理及監督氣候相關風險和機遇的管治流程、監控措施及程序中的角色，包括以下資訊：</p> <p>(i) whether the role is delegated to a specific management-level position or management-level committee and how oversight is exercised over that position or committee; and</p> <p>(i) 該角色是否被委託給特定的管理層人員或管理層委員會以及如何對該人員或委員會進行監督；及</p> <p>(ii) whether management uses controls and procedures to support the oversight of climate-related risks and opportunities and, if so, how these controls and procedures are integrated with other internal functions.</p> <p>(ii) 管理層可有使用監控措施及程序協助監督氣候相關風險和機遇；如有，這些監控措施及程序如何與其他內部職能部門進行整合。</p>	GOVERNANCE 管治
<p>(II) Strategy (II) 策略</p>	
<p>Climate-related risks and opportunities 氣候相關風險和機遇</p>	
<p>20. An issuer shall disclose information to enable an understanding of climate-related risks and opportunities that could reasonably be expected to affect the issuer’s cash flows, its access to finance or cost of capital over the short, medium or long term. Specifically, the issuer shall:</p> <p>20. 發行人須披露其資訊，以讓人理解其合理預期可能在短期、中期或長期影響其現金流量、融資渠道或資本成本的氣候相關風險和機遇。具體而言，發行人須：</p>	

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
<p>(a) describe climate-related risks and opportunities that could reasonably be expected to affect the issuer's cash flows, its access to finance or cost of capital over the short, medium or long term;</p> <p>(a) 描述合理預期可能在短期、中期或長期影響發行人的現金流量、融資渠道或資本成本的氣候相關風險和機遇；</p> <p>(b) explain, for each climate-related risk the issuer has identified, whether the issuer considers the risk to be a climate-related physical risk or climate-related transition risk;</p> <p>(b) 就發行人已識別的每項氣候相關風險，解釋發行人是否認為該風險是與氣候相關物理風險或與氣候相關轉型風險；</p> <p>(c) specify, for each climate-related risk and opportunity the issuer has identified, over which time horizons – short, medium or long term – the effects of each climate-related risk and opportunity could reasonably be expected to occur; and</p> <p>(c) 就發行人已識別的每項氣候相關風險和機遇，具體說明其合理預期可能影響發行人的時間範圍(短期、中期或長期)；及</p> <p>(d) explain how the issuer defines 'short term', 'medium term' and 'long term' and how these definitions are linked to the planning horizons used by the issuer for strategic decision-making.</p> <p>(d) 解釋發行人如何定義短期、中期及長期，以及這些定義如何與其策略決定規劃範圍掛鉤。</p>	STRATEGY 策略
Business model and value chain 業務模式和價值鏈	
<p>21. An issuer shall disclose information that enables an understanding of the current and anticipated effects of climate-related risks and opportunities on the issuer's business model and value chain. Specifically, the issuer shall disclose:</p> <p>21. 發行人須披露讓人了解氣候相關風險和機遇對其業務模式和價值鏈的當前和預期影響的資訊。具體而言，發行人須作如下披露：</p>	
<p>(a) a description of the current and anticipated effects of climate-related risks and opportunities on the issuer's business model and value chain; and</p> <p>(a) 描述氣候相關風險和機遇對發行人的業務模式和價值鏈的當前和預期影響；及</p> <p>(b) a description of where in the issuer's business model and value chain climate related risks and opportunities are concentrated (for example, geographical areas, facilities and types of assets).</p> <p>(b) 描述在發行人的業務模式和價值鏈中，氣候相關風險和機遇集中的地方(例如，地理區域、設施及資產類型)。</p>	STRATEGY 策略

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
Strategy and decision-making 策略和決策	
<p>22. An issuer shall disclose information that enables an understanding of the effects of climate-related risks and opportunities on its strategy and decision-making. Specifically, the issuer shall disclose:</p> <p>22. 發行人須披露讓人了解氣候相關風險和機遇對其策略和決策的影響的資訊。具體而言，發行人須披露：</p>	
<p>(a) information about how the issuer has responded to, and plans to respond to, climate-related risks and opportunities in its strategy and decision-making, including how the issuer plans to achieve any climate-related targets it has set and any targets it is required to meet by law or regulation. Specifically, the issuer shall disclose information about:</p> <p>(a) 有關發行人已經及將來計劃在其策略和決策中如何應對氣候相關風險和機遇的資訊，包括發行人計劃如何實現任何其所設定的氣候相關目標，以及任何法律或法規要求達到的目標。具體而言，發行人須披露以下資訊：</p> <p>(i) current and anticipated changes to the issuer's business model, including its resource allocation, to address climate-related risks and opportunities;</p> <p>(i) 因應氣候相關風險和機遇而在當前及預期將來對發行人業務模式(包括資源配置)作出的變動；</p> <p>(ii) current and anticipated adaptation and mitigation efforts (whether direct or indirect);</p> <p>(ii) 已經或預期將進行的任何適應或減緩工作(直接或間接)；</p> <p>(iii) any climate-related transition plan the issuer has (including information about key assumptions used in developing its transition plan, and dependencies on which the issuer's transition plan relies), or an appropriate negative statement where the issuer does not have a climate-related transition plan; and</p> <p>(iii) 發行人任何與氣候相關轉型計劃(包括制定轉型計劃時使用的主要假設的資訊，以及該計劃所依賴的因素)，或若發行人並未有這樣的計劃，則作適當的否定聲明；及</p> <p>(iv) how the issuer plans to achieve any climate-related targets (including any greenhouse gas emissions targets (if any)), described in accordance with paragraphs 37 to 40; and</p> <p>(iv) 發行人計劃如何實現第37至40段所述的任何氣候相關目標(包括任何溫室氣體排放目標(如有))；及</p> <p>(b) information about how the issuer is resourcing, and plans to resource, the activities disclosed in accordance with paragraph 22(a).</p> <p>(b) 有關發行人當前及將來計劃如何為根據第22(a)段披露的行動提供資源。</p>	<p>STRATEGY 策略 RESOURCE STEWARDSHIP & CIRCULARITY 資源管理與循環發展</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
<p>23. An issuer shall disclose information about the progress of plans disclosed in previous reporting periods in accordance with paragraph 22(a).</p> <p>23. 發行人須披露先前各匯報期內按照第22(a)段所披露計劃的進度。</p>	<p>STRATEGY 策略</p> <p>RESOURCE STEWARDSHIP & CIRCULARITY 資源管理與循環發展</p>
<p>Financial position, financial performance and cash flows 財務狀況、財務表現及現金流量</p>	
<p>Current financial effect 當前財務影響</p>	
<p>24. An issuer shall disclose qualitative and quantitative information about:</p> <p>24. 發行人須披露以下定性和量化資料：</p>	
<p>(a) how climate-related risks and opportunities have affected its financial position, financial performance and cash flows for the reporting period; and</p> <p>(a) 氣候相關風險和機遇如何影響發行人在匯報期的財務狀況、財務表現及現金流量；及</p> <p>(b) the climate-related risks and opportunities identified in paragraph 24(a) for which there is a significant risk of a material adjustment within the next annual reporting period to the carrying amounts of assets and liabilities reported in the related financial statements.</p> <p>(b) 當存在將導致下一匯報年度相關財務報表中的資產和負債賬面價值發生重要調整的重大風險時，關於第24(a)段中識別的氣候相關風險和機遇的資訊。</p>	<p>STRATEGY 策略</p> <p>FINANCIAL POSITION, FINANCIAL PERFORMANCE AND CASH FLOWS 財務狀況、財務表現及 現金流量</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
Anticipated financial effect 預期財務影響	
25. The issuer shall provide qualitative and quantitative disclosures about: 25. 發行人須披露以下定性和量化資料：	
<ul style="list-style-type: none"> (a) how the issuer expects its financial position to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities, taking into consideration: (a) 發行人經考慮其管理氣候相關風險和機遇的策略後，並考慮到以下各項，預期其財務狀況在短期、中期及長期內將如何變化： <ul style="list-style-type: none"> (i) its investment and disposal plans; and (i) 其投資及處置計劃；及 (ii) its planned sources of funding to implement its strategy; and (ii) 其為實施策略所需的資金的計劃資金來源；及 (b) how the issuer expects its financial performance and cash flows to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities. (b) 基於發行人管理氣候相關風險和機遇的策略，其預計其財務業績及現金流量在短期、中期及長期的變化。 	STRATEGY 策略 FINANCIAL POSITION, FINANCIAL PERFORMANCE AND CASH FLOWS 財務狀況、財務表現及現金流量
Climate resilience 氣候韌性	
26. An issuer shall disclose information that enables an understanding of the resilience of the issuer's strategy and business model to climate-related changes, developments and uncertainties, taking into consideration the issuer's identified climate-related risks and opportunities. An issuer shall use climate-related scenario analysis to assess its climate resilience using an approach that is commensurate with an issuer's circumstances. In providing quantitative information, the issuer may disclose a single amount or a range. Specifically, the issuer shall disclose: 26. 在考慮發行人已識別的氣候相關風險和機遇後，發行人須披露信息，使他人了解發行人的策略及業務模式對氣候相關變化、發展或不確定性的韌性。發行人須按與其情況相稱的做法，使用與氣候相關的情景分析來評估其氣候韌性韌性。提供量化信息時，發行人可披露單一數額或區間範圍。具體而言，發行人須披露：	

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
<p>(a) the issuer's assessment of its climate resilience as at the reporting date, which shall enable an understanding of:</p> <p>(a) 發行人截至匯報日對其氣候韌性的評估，其有助於了解：</p> <p>(i) the implications, if any, of the issuer's assessment for its strategy and business model, including how the issuer would need to respond to the effects identified in the climate-related scenario analysis;</p> <p>(i) 發行人的分析結果對其策略和業務模式的影響(如有)，包括發行人需要如何應對氣候相關情景分析中確定的影響；</p> <p>(ii) the significant areas of uncertainty considered in the issuer's assessment of its climate resilience; and</p> <p>(ii) 發行人對氣候韌性的評估中考慮的重大不確定因素的範疇；及</p> <p>(iii) the issuer's capacity to adjust, or adapt its strategy and business model to climate change over the short, medium or long term;</p> <p>(iii) 發行人根據氣候發展調整其短期、中期和長期策略和業務模式的能力；</p>	<p>CLIMATE RESILIENCE 氣候韌性</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
<p>(b) how and when the climate-related scenario analysis was carried out, including:</p> <p>(b) 如何及何時進行氣候相關情景分析，包括：</p> <p>(i) information about the inputs used, including:</p> <p>(i) 使用的輸入數據，包括：</p> <p>(1) which climate-related scenarios the issuer used for the analysis and the sources of such scenarios;</p> <p>(1) 發行人在分析中使用的氣候相關情景及其來源；</p> <p>(2) whether the analysis included a diverse range of climate-related scenarios;</p> <p>(2) 分析是否涵蓋多種不同的氣候相關情景；</p> <p>(3) whether the climate-related scenarios used for the analysis are associated with climate-related transition risks or climate-related physical risks;</p> <p>(3) 分析所使用的氣候相關情景是否與氣候相關轉型風險或氣候相關物理風險有關；</p> <p>(4) whether the issuer used, among its scenarios, a climate-related scenario aligned with the latest international agreement on climate change;</p> <p>(4) 發行人在其情景中是否使用了與最新氣候變化國際協議相一致的情景；</p> <p>(5) why the issuer decided that its chosen climate-related scenarios are relevant to assessing its resilience to climate-related changes, developments or uncertainties;</p> <p>(5) 發行人為何認為所選擇的氣候相關情景與評估其氣候相關變化、發展或不確定性的適應能力相關；</p> <p>(6) time horizons the issuer used in the analysis; and</p> <p>(6) 發行人在分析中所使用的時間範圍；及</p> <p>(7) what scope of operations the issuer used in the analysis (for example, the operation, locations and business units used in the analysis);</p> <p>(7) 發行人分析所涵蓋的營運範圍(例如分析所涵蓋的營運地點及業務單位)；</p> <p>(ii) the key assumptions the issuer made in the analysis; and</p> <p>(ii) 發行人在分析中所作的關鍵假設；及</p> <p>(iii) the reporting period in which the climate-related scenario analysis was carried out.</p> <p>(iii) 進行氣候相關情景分析的匯報期。</p>	<p>RISK MANAGEMENT 風險管理</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
(III) Risk Management (III) 風險管理	
27. An issuer shall disclose information about: 27. 發行人須披露以下資訊：	
<p>(a) the processes and related policies it uses to identify, assess, prioritise and monitor climate-related risks, including information about:</p> <p>(a) 發行人用於識別、評估氣候相關風險，以及釐定當中輕重緩急並保持監察的流程及相關政策，包括有關以下方面的資訊：</p> <p>(i) the inputs and parameters the issuer uses (for example, information about data sources and the scope of operations covered in the processes);</p> <p>(i) 發行人使用的輸入資料及參數(例如資料來源及程序所涵蓋的業務範圍)；</p> <p>(ii) whether and how the issuer uses climate-related scenario analysis to inform its identification of climate-related risks;</p> <p>(ii) 發行人可有及如何使用氣候相關情景分析來識別氣候相關風險；</p> <p>(iii) how the issuer assesses the nature, likelihood and magnitude of the effects of those risks (for example, whether the issuer considers qualitative factors, quantitative thresholds or other criteria);</p> <p>(iii) 發行人如何評估有關風險的影響的性質、可能性及程度(例如發行人可有考慮定性因素、量化門檻或其他所用標準)；</p> <p>(iv) whether and how the issuer prioritises climate-related risks relative to other types of risks;</p> <p>(iv) 發行人可有及如何就氣候相關風險相對於其他類型風險的優次排列；</p> <p>(v) how the issuer monitors climate-related risks; and</p> <p>(v) 發行人如何監察其氣候相關風險；及</p> <p>(vi) whether and how the issuer has changed the processes it uses compared with the previous reporting period;</p> <p>(vi) 與上一個匯報期相比，發行人可有及如何改變其使用的流程；</p>	<p>THIS IS THE GROUP'S INAUGURAL ESG REPORT, THEREFORE THERE ARE NO CHANGES IN PROCESSES COMPARED TO THE PREVIOUS REPORTING PERIOD TO DISCLOSE.</p> <p>本報告為本集團首份 ESG 報告，因此並無與上一匯報期相關的流程變更可供披露。</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
<ul style="list-style-type: none"> (b) the processes the issuer uses to identify, assess, prioritise and monitor climate related opportunities (including information about whether and how the issuer uses climate-related scenario analysis to inform its identification of climate-related opportunities); and (b) 發行人用於識別、評估氣候相關機遇，以及釐定當中輕重緩急並保持監察的流程(包括發行人可有及如何使用氣候相關情景分析來確定氣候相關機遇的資訊)；及 (c) the extent to which, and how, the processes for identifying, assessing, prioritising and monitoring climate-related risks and opportunities are integrated into and inform the issuer's overall risk management process. (c) 氣候相關風險和機遇的識別、評估、優次排列和監察流程，是如何融入發行人的整體風險管理流程，以及融入的程度如何。 	
(IV) Metrics and Targets (IV) 指標及目標	
Greenhouse gas emissions 溫室氣體排放	
28. An issuer shall disclose its absolute gross greenhouse gas emissions generated during the reporting period, expressed as metric tons of CO2 equivalent, classified as: 28. 發行人須披露匯報期內的溫室氣體絕對總排放量(以公噸二氧化碳當量表示)，並分為：	
<ul style="list-style-type: none"> (a) Scope 1 greenhouse gas emissions; (a) 範圍1溫室氣體排放； (b) Scope 2 greenhouse gas emissions; and (b) 範圍2溫室氣體排放；及 (c) Scope 3 greenhouse gas emissions. (c) 範圍3溫室氣體排放。 	METRICS AND TARGETS 指標及目標

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
29. An issuer shall: 29. 發行人須：	
<p>(a) measure its greenhouse gas emissions in accordance with the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (2004) unless required by a jurisdictional authority or another exchange on which the issuer is listed to use a different method for measuring greenhouse gas emissions;</p> <p>(a) 除非管轄機關或發行人上市之另一交易所另有要求，否則發行人須根據《溫室氣體核算體系：企業核算與報告標準(2004年)》計量其溫室氣體排放；</p> <p>(b) disclose the approach it uses to measure its greenhouse gas emissions including:</p> <p>(b) 披露其用於計量溫室氣體排放的方法，包括：</p> <p>(i) the measurement approach, inputs and assumptions the issuer uses to measure its greenhouse gas emissions;</p> <p>(i) 發行人用於計量其溫室氣體排放的計量方法、輸入資料及假設；</p> <p>(ii) the reason why the issuer has chosen the measurement approach, inputs and assumptions it uses to measure its greenhouse gas emissions; and</p> <p>(ii) 發行人為何選擇該計量方法、輸入資料及假設計量溫室氣體排放；及</p> <p>(iii) any changes the issuer made to the measurement approach, inputs and assumptions during the reporting period and the reasons for those changes;</p> <p>(iii) 發行人在匯報期對計量方法、輸入資料及假設進行的任何變更以及變更原因；</p> <p>(c) for Scope 2 greenhouse gas emissions disclosed in accordance with paragraph 28(b), disclose its location-based Scope 2 greenhouse gas emissions, and provide information about any contractual instruments that is necessary to enable an understanding of the issuer's Scope 2 greenhouse gas emissions; and</p> <p>(c) 就根據第28(b)段披露的範圍2溫室氣體排放，披露其以地域為基準的範圍2溫室氣體排放，並提供有助於了解該排放的任何所需合約文書的資訊；及</p> <p>(d) for Scope 3 greenhouse gas emissions disclosed in accordance with paragraph 28(c), disclose the categories included within the issuer's measure of Scope 3 greenhouse gas emissions, in accordance with the Scope 3 categories described in the Greenhouse Gas Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard (2011).</p> <p>(d) 就根據第28(c)段披露的範圍3溫室氣體排放，根據《溫室氣體核算體系：企業價值鏈(範圍3)核算與報告標準(2011年)》所述的範圍3類別披露發行人計量範圍3溫室氣體排放中包含的類別。</p>	<p>THIS IS THE GROUP'S INAUGURAL ESG REPORT, THEREFORE THERE ARE NO CHANGES TO THE MEASUREMENT APPROACH, INPUTS AND ASSUMPTIONS TO DISCLOSE.</p> <p>本報告為本集團首份 ESG 報告，因此並無與計量方法、輸入資料及假設相關的變更可供披露。</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所《環境、社會及管治報告守則》披露要求	Section and Remarks 章節及備註
Climate-related transition risks 氣候相關轉型風險	
<p>30. An issuer shall disclose the amount and percentage of assets or business activities vulnerable to climate-related transition risks.</p> <p>30. 發行人須披露容易受氣候相關轉型風險影響的資產或業務活動的金額及百分比。</p>	<p>THE GROUP HAS NOT YET CONDUCTED A SCENARIO ANALYSIS. FURTHER INFORMATION WILL BE DISCLOSED IN FUTURE REPORTS. 本集團尚未進行情境分析。更多信息將在未來的報告中披露。</p>
Climate-related physical risks 氣候相關物理風險	
<p>31. An issuer shall disclose the amount and percentage of assets or business activities vulnerable to climate-related physical risks.</p> <p>31. 發行人須披露容易受氣候相關物理風險影響的資產或業務活動的金額及百分比。</p>	<p>THE GROUP HAS NOT YET CONDUCTED A SCENARIO ANALYSIS DUE TO A LACK OF INTERNAL RESOURCES. FURTHER INFORMATION WILL BE DISCLOSED IN FUTURE REPORTS. 本集團因內部資源有限，尚未進行情境分析。更多信息將在未來的報告中披露。</p>
Climate-related opportunities 氣候相關機遇	
<p>32. An issuer shall disclose the amount and percentage of assets or business activities aligned with climate-related opportunities.</p> <p>32. 發行人須披露涉及氣候相關機遇的資產或業務活動的金額及百分比。</p>	<p>THE GROUP HAS NOT YET CONDUCTED A SCENARIO ANALYSIS DUE TO A LACK OF INTERNAL RESOURCES. FURTHER INFORMATION WILL BE DISCLOSED IN FUTURE REPORTS. 本集團因內部資源有限，尚未進行情境分析。更多信息將在未來的報告中披露。</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所環境、社會及管治報告守則規定	Section and Remarks 章節及備註
Capital deployment 資本運用	
<p>33. An issuer shall disclose the amount of capital expenditure, financing or investment deployed towards climate-related risks and opportunities.</p> <p>33. 發行人須披露用於氣候相關風險和機遇的資本開支、融資或投資的金額。</p>	<p>DURING THE REPORTING PERIOD, THE GROUP DID NOT INCUR MATERIAL CAPITAL EXPENDITURE, FINANCING OR INVESTMENT SPECIFICALLY DIRECTED TOWARDS CLIMATE-RELATED RISKS OR OPPORTUNITIES. THIS REFLECTS THAT EXISTING OPERATIONS AND PROJECTS DID NOT REQUIRE SIGNIFICANT NEW CAPITAL ALLOCATION IN THIS AREA. NEVERTHELESS, CLIMATE CONSIDERATIONS REMAIN INTEGRATED INTO OUR BROADER INVESTMENT AND OPERATIONAL DECISION-MAKING PROCESSES, AND WE CONTINUE TO MONITOR OPPORTUNITIES FOR FUTURE DEPLOYMENT WHERE MATERIAL IMPACTS OR BENEFITS CAN BE ACHIEVED.</p> <p>於報告期間，本集團並無發生專門針對氣候相關風險或機遇的重大資本支出、融資或投資。這反映現有營運及項目無需於該領域投入大量新的資金。儘管如此，氣候因素仍融入我們更廣泛的投資及營運決策過程中，我們將繼續關注未來部署的機會，以便在可能產生重大影響或效益的領域採取行動。</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所環境、社會及管治報告守則規定	Section and Remarks 章節及備註
Internal carbon prices 內部碳定價	
34. An issuer shall disclose: 34. 發行人須披露如下：	
<p>(a) an explanation of whether and how the issuer is applying a carbon price in decision-making (for example, investment decisions, transfer pricing, and scenario analysis); and</p> <p>(a) 闡釋發行人可有及如何在決策中應用碳定價(例如投資決策、轉移定價及情景分析)；及</p> <p>(b) the price of each metric tonne of greenhouse gas emissions the issuer uses to assess the costs of its greenhouse gas emissions; or an appropriate negative statement that the issuer does not apply a carbon price in decision-making.</p> <p>(b) 發行人用於評估其溫室氣體排放成本的每公噸溫室氣體排放量定價；或適當的否定聲明，確認發行人沒有在決策中應用碳定價。</p>	<p>THE GROUP CURRENTLY DID NOT APPLY CARBON PRICE IN DECISION-MAKING.</p> <p>本集團目前於決策中並未應用碳定價。</p>
Remuneration 薪酬	
<p>35. An issuer shall disclose whether and how climate-related considerations are factored into remuneration policy, or an appropriate negative statement. This may form part of the disclosure under paragraph 19(a)(iv).</p> <p>35. 發行人須披露氣候相關考慮因素可有及如何納入薪酬政策，或提供適當的否定聲明。這可能構成根據第19(a)(iv)段作出的披露的一部分。</p>	<p>GOVERNANCE</p> <p>管治</p>
Industry-based metrics 行業指標	
<p>36. An issuer is encouraged to disclose industry-based metrics that are associated with one or more particular business models, activities or other common features that characterise participation in an industry. In determining the industry-based metrics that the issuer discloses, an issuer is encouraged to refer to and consider the applicability of the industry-based metrics associated with disclosure topics described in the IFRS S2 Industry-based Guidance on implementing Climate-related Disclosures and other industry-based disclosure requirements prescribed under other international ESG reporting frameworks.</p> <p>36. 本交易所鼓勵發行人披露與一項或多項特定的業務模式和活動有關的行業指標，或與參與有關行業常見特徵有關的行業指標。在決定披露哪些行業指標時，本交易所鼓勵發行人參考《〈國際財務報告可持續披露準則S2號〉行業披露指南》和其他國際環境、社會及管治報告框架規定的行業披露要求所述的與披露主題相關的行業指標，並考慮其是否適用。</p>	<p>NOT APPLICABLE</p> <p>不適用</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所環境、社會及管治報告守則規定	Section and Remarks 章節及備註
Climate-related targets 氣候相關目標	
<p>37. An issuer shall disclose (a) the qualitative and quantitative climate-related targets the issuer has set to monitor progress towards achieving its strategic goals; and (b) any targets the issuer is required to meet by law or regulation, including any greenhouse gas emissions targets. For each target, the issuer shall disclose:</p> <p>37. 發行人須披露(a)其為監察實現其策略目標的進展而設定的與氣候相關的定性及量化目標；及(b)法律或法規要求發行人達到的任何目標，包括任何溫室氣體排放目標。發行人須就每個目標逐一披露：</p>	
<p>(a) the metric used to set the target; (a) 用以設定目標的指標；</p> <p>(b) the objective of the target (for example, mitigation, adaptation or conformance with science-based initiatives); (b) 目標的目的(例如減緩、適應或以科學為基礎的舉措)；</p> <p>(c) the part of the issuer to which the target applies (for example, whether the target applies to the issuer in its entirety or only a part of the issuer, such as a specific business unit or geographic region); (c) 目標的適用範圍(例如目標是適用於發行人整個集團還是部分(如僅適用於某個業務單位或地理區域))；</p> <p>(d) the period over which the target applies; (d) 目標的適用期間；</p> <p>(e) the base period from which progress is measured; (e) 衡量進度的基準期間；</p> <p>(f) milestones or interim targets (if any); (f) 階段性目標或中期目標(如有)；</p> <p>(g) if the target is quantitative, whether the target is an absolute target or an intensity target; and (g) 如屬量化目標，其屬絕對目標還是強度目標；及</p> <p>(h) how the latest international agreement on climate change, including jurisdictional commitments that arise from that agreement, has informed the target. (h) 最新氣候變化國際協議(包括該協議產生的司法承諾)如何幫助發行人設定目標。</p>	<p>METRICS AND TARGETS 指標及目標 RESOURCE STEWARDSHIP & CIRCULARITY 資源管理與循環發展</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所環境、社會及管治報告守則規定	Section and Remarks 章節及備註
<p>38. An issuer shall disclose information about its approach to setting and reviewing each target, and how it monitors progress against each target, including:</p> <p>38. 發行人須披露其設定及審核每項目標的方法，以及其如何監察達標進度，包括：</p> <ul style="list-style-type: none"> (a) whether the target and the methodology for setting the target has been validated by a third party; (a) 目標本身及設定目標的方法是否經第三方驗證； (b) the issuer's processes for reviewing the target; (b) 發行人審核目標的程序； (c) the metrics used to monitor progress towards reaching the target; and (c) 用於監察達標進度的指標；及 (d) any revisions to the target and an explanation for those revisions. (d) 任何修訂目標的內容及原因。 	<p>THIS REPORT HAS NOT BEEN VALIDATED BY A THIRD PARTY. 目前本報告內容未經第三方驗證。</p> <p>THIS IS THE GROUP'S INAUGURAL ESG REPORT, THEREFORE NO PREVIOUS TARGETS HAVE BEEN ESTABLISHED AND THERE ARE NO REVISIONS TO TARGETS TO DISCLOSE. 本報告為本集團首份ESG報告，因此並無設定過往目標，亦無任何目標修訂可供披露。</p>
<p>39. An issuer shall disclose information about its performance against each climate-related target and an analysis of trends or changes in the issuer's performance.</p> <p>39. 發行人須披露有關每項氣候相關目標的績效的資訊以及對發行人績效的趨勢或變化分析。</p>	<p>AS THIS IS THE FIRST YEAR FOR CLOUDBREAK TO PUBLISH AN ESG REPORT AND ESTABLISH CLIMATE-RELATED TARGETS, PERFORMANCE DATA AND TREND ANALYSIS ARE NOT YET AVAILABLE. GOING FORWARD, WE WILL MONITOR PROGRESS AGAINST THESE TARGETS, DISCLOSE PERFORMANCE OUTCOMES, AND PROVIDE ANALYSIS OF TRENDS TO ENSURE TRANSPARENCY AND ACCOUNTABILITY IN OUR CLIMATE STRATEGY. 由於撥康視雲首次發佈ESG報告及制定氣候相關目標，因此尚無績效數據及趨勢分析可供參考。展望未來，我們將監控該等目標的進展狀況，披露績效結果，並提供趨勢分析，以確保氣候策略的透明度及問責制。</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所環境、社會及管治報告守則規定	Section and Remarks 章節及備註
<p>40. For each greenhouse gas emissions target disclosed in accordance with paragraphs 37 to 39, an issuer shall disclose:</p> <p>40. 就按第37至39段披露的每一項溫室氣體排放目標，發行人須披露：</p>	
<p>(a) which greenhouse gases are covered by the target; (a) 目標涵蓋哪些溫室氣體；</p> <p>(b) whether Scope 1, Scope 2 or Scope 3 greenhouse gas emissions are covered by the target; (b) 目標是否涵蓋範圍1、範圍2或範圍3溫室氣體排放；</p> <p>(c) whether the target is a gross greenhouse gas emissions target or a net greenhouse gas emissions target. If the issuer discloses a net greenhouse gas emissions target, the issuer is also required to separately disclose its associated gross greenhouse gas emissions target; (c) 此目標是溫室氣體排放總量目標還是溫室氣體排放淨額目標。如為溫室氣體排放淨額目標，發行人須另外披露相關的溫室氣體排放總量目標；</p> <p>(d) whether the target was derived using a sectoral decarbonisation approach; and (d) 目標是否是採用行業脫碳方法得出的；及</p>	<p>AS THIS IS THE FIRST YEAR FOR CLOUDBREAK TO PUBLISH AN ESG REPORT AND ESTABLISH CLIMATE-RELATED TARGETS, PERFORMANCE DATA AND TREND ANALYSIS ARE NOT YET AVAILABLE.</p> <p>WHILE WE ARE STILL EXPANDING OUR BUSINESS, WE RECOGNISE THE IMPORTANCE OF SETTING CLEAR PATHWAYS FOR CARBON REDUCTION. IN THE COMING YEARS, WE WILL SET MORE AMBITIOUS TARGETS, MONITOR PROGRESS CLOSELY, AND DISCLOSE PERFORMANCE OUTCOMES TO ENSURE TRANSPARENCY AND ACCOUNTABILITY IN OUR CLIMATE STRATEGY.</p> <p>由於撥康視雲首次發佈ESG報告及制定氣候相關目標，因此尚無績效數據及趨勢分析可供參考。</p> <p>儘管我們仍在拓展業務，但我們深知制定明確的碳減排路徑至關重要。未來幾年，我們將制定更積極的目標，密切監控進度，並披露績效結果，以確保氣候策略的透明度及問責制。</p>

Climate-related Disclosures 氣候相關披露	
HKEX ESG Reporting Code Requirements 香港交易所環境、社會及管治報告守則規定	Section and Remarks 章節及備註
<p>(e) the issuer's planned use of carbon credits to offset greenhouse gas emissions to achieve any net greenhouse gas emissions target. In explaining its planned use of carbon credits, the issuer shall disclose:</p> <p>(e) 發行人計劃使用碳信用抵銷溫室氣體排放以實現任何溫室氣體排放淨額目標。關於使用碳信用的計劃，發行人須披露：</p> <p>(i) the extent to which, and how, achieving any net greenhouse gas emissions target relies on the use of carbon credits;</p> <p>(i) 依賴使用碳信用以實現任何溫室氣體排放淨額目標的程度及方式；</p> <p>(ii) which third-party scheme(s) will verify or certify the carbon credits;</p> <p>(ii) 該碳信用將由哪些第三方計劃驗證或認證；</p> <p>(iii) the type of carbon credit, including whether the underlying offset will be nature-based or based on technological carbon removals, and whether the underlying offset is achieved through carbon reduction or removal; and</p> <p>(iii) 碳信用的類型，包括相關抵銷是否是基於自然還是基於科技的碳消除，以及相關抵銷是通過減碳還是碳消除實現；及</p> <p>(iv) any other factors necessary to enable an understanding of the credibility and integrity of the carbon credits the issuer plans to use (for example, assumptions regarding the permanence of the carbon offset).</p> <p>(iv) 為讓人了解發行人計劃使用的碳信用的可信度和完整性所必需的任何其他重要因素(例如，對碳抵銷效果的假設)。</p>	<p>NOT APPLICABLE 不適用</p>
Applicability of cross-industry metrics and industry-based metrics 跨行業指標及行業指標的適用性	
<p>41. In preparing disclosures to meet the requirements in paragraphs 21 to 26 and 37 to 38, an issuer shall refer to and consider the applicability of cross-industry metrics (see paragraphs 28 to 35) and (ii) industry-based metrics (see paragraph 36).</p> <p>41. 在編製披露內容以符合第21至26及37至38段的規定時，發行人須參考(i)跨行業指標(見第28至35段)及(ii)行業指標(見第36段)並考慮其是否適用。</p>	<p>NOT APPLICABLE 不適用</p>



拨康视云™

Cloudbreak Pharma